Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 1 of 102 
CONFIDE NTIAL               06 AUG 2020  
 
CONFIDE NTIAL  
A Multicenter, Randomized, Double -Blinded, Vehicle -Controlled Study to 
Evaluate the Safety and Efficacy of  Topi[INVESTIGATOR_563573], 15%  in Subjects with Axillary Hyperhidrosis  (the ‚ÄúCardigan I I Study ‚Äù) 
PROTOCOL NUMBER:  BBI-[ADDRESS_740437]:  Sofpi[INVESTIGATOR_563574]  (BBI -4000 )  
ORIGI NAL PROTOCOL  September 27, [ADDRESS_740438] 6, 2020 
SPO NSOR:  
 Brickell Biotech, Inc. [ADDRESS_740439]. , Suite 102 
Boulder , CO [ZIP_CODE]  
PHASE:  3 (Pi[INVESTIGATOR_22735] ) 
IND NUMBER : 121,256  
MEDICAL MO NITOR : IQVIA Medical Monitor Fax: [PHONE_9053] (US Toll -free: 1 -866-761-
1274 ) 
Email: safety -[EMAIL_207]   
 
Copyright 201 9 Brickell Biotech, Inc.  All rights reserved.  Unauthorized copying or use of this information is 
prohibited.  

Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 2 of 102 
CONFIDE NTIAL                06 AUG 2020  
SPO NSOR  SIGNATORY:  
 
 
   
Deepak Chadha , MS, MBA, RAC  Chief Research and Development Officer  Date  
 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 3 of 102 
CONFIDE NTIAL                06 AUG 2020  
INVESTIGATOR  SIGNATURE  [CONTACT_1783]  
I agree to:  
 
‚Ä¢ Implement and conduct this study diligently and in strict compliance with the protocol, Good C linical 
Practice (GCP), and all applicable laws and regulations.  
 
‚Ä¢ Maintain all information supplied by [CONTACT_563638], Inc. in confidence and, when this informa tion is 
submitted to an Institutional Review Board (IRB) or another group, it will  be submitted with a designation 
that the material is confidential.  
 
 
I have read this protocol in its entirety and I agree to all aspects.  
 
 
 
 
___________________________________________________________________________ 
Investigator Printed Name    [CONTACT_563676][INVESTIGATOR_563572]-4000- CL-302/03 Page 4 of 102 
CONFIDE NTIAL                06 AUG 2020  
TABLE OF CO NTENTS 
SPO NSOR SIG NATORY:  ................................................................................................ ......................... [ADDRESS_740440] (IP)  ............................................................................................ [ADDRESS_740441]  ........................................ 24  
5.3 Instructions for the Subjects  ......................................................................................................... 25  
5.4 Procedures for Blinding and Unblinding  ..................................................................................... 26  
6 CONCOMITA NT MEDICATIO NS/TREATME NTS .................................................................... 26  
6.1 Permissible Medications/Treatments  ........................................................................................... 26  
6.2 Prohibited Medications/Treatments  ............................................................................................. 27  
7 PROCEDURES  ................................................................................................................................... 27  
7.1 Time and Events Table  .................................................................................................................. 29  
7.2 Visit -Specific Procedures  ............................................................................................................... 31  
7.2.1  Visit 1: Screening (Days -31 to 0) ............................................................................................. 31  
7.2.2  Visits 2 and 3: GSP1 and GSP2  ................................................................................................ 32  
7.2.3  Visit 4: GSP3 (Day 1; Rescreening/Baseline) +14 Days of Visit 2  ......................................... 32  
7.2.4  Visit 5: Day 8 ¬± 2 Days .............................................................................................................. 33  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 5 of 102 
CONFIDE NTIAL                06 AUG 2020  
7.2.5  Visit 6: Day 15 ¬± 2 Days ............................................................................................................ 33  
7.2.6  Visit 7: Day 22 ¬± 2 Days ............................................................................................................ 34  
7.2.7  Visit 8: Day 29 ¬± 2 Days ............................................................................................................ 34  
7.2.8  Visit 9: Day 36 ¬± 2 Days ............................................................................................................ 35  
7.2.9  Visits 10 and 11: GSP4 (Day 41) ¬± 2 Days and GSP 5 (Day 42) ¬± 2 Days ............................ 35  
7.2.10  Visit 12: GSP6 (Day 43; End of Treatment) ¬± 2 Days ............................................................ 36  
7.2.11  Visit 13: Follow -up (Day 57) ¬± [ADDRESS_740442] Dermatitis (Skin Sensitization) Assessment  ............................................... 40  
8.2 Summary of Methods of Data Collection  ..................................................................................... 40  
8.3 Efficacy Measures  .......................................................................................................................... 40  
9 ADVERSE EVE NTS (AE) A ND SERIOUS ADVERSE EVE NTS (SAE)  .................................... [ADDRESS_740443] Abnormalities  .......................................... 44  
9.5 Pregnancy Reporting  ..................................................................................................................... 45  
9.5.1  Time Period for Collecting Pregnancy Information  .............................................................. 45  
9.5.2  Action to Be Taken If Pregnancy Occurs  ................................................................................ 45  
9.6 Other Safety Measures  .................................................................................................................. 46  
10 STATISTICAL PROCEDUR ES ....................................................................................................... 46  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740444] Groups  ................................................................ 56  
11.2  Compliance with Protocol  ............................................................................................................. 57  
11.3  Study Termination  ......................................................................................................................... 57  
12 ADMI NISTRATIVE ISSUE S ............................................................................................................ 57  
12.1  Posting of Information on Clinicaltrials.gov  ............................................................................... 57  
12.2  Protection of Human Subjects  ...................................................................................................... 57  
12.2.1  Compliance with Informed Consent Regulations (US 21 CFR Part 50) and Relevant 
Country Regulations ................................................................................................................. 57  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740445] ............... 59  
12.6.1  Labeling/Packaging ................................................................................................................... [ADDRESS_740446]  ....................................................................... 59  
12.7  Monitoring by [CONTACT_1034]  ............................................................................................................ 60  
12.8  Publications  ..................................................................................................................................... 60  
13 REFERE NCES  .................................................................................................................................... 61  
14 APPE NDICES  ..................................................................................................................................... 62  
APPE NDIX 1:  GRAVIMETRICALLY MEASURED SW EAT PRODUCTIO N ............................. 63  
APPE NDIX 2:  HYPERHIDROSIS DISEASE SEVERITY MEASURE -AXILLARY  (HDSM -
AXÔõô¬ï<($562)$*(  (VERSIO N 1.3) ................................................................................. 64  
APPE NDIX 3:  HYPERHIDROSIS DISEASE SEVERITY MEASURE -AXILLARY &+,/'¬ï
72$(<ﬁí562)$*(  ................................................................................................................. 67  
APPE NDIX 4:  DERMATOLOGY LIFE QUALITY I NDEX -AXILLA; FOR  SUBJECTS  ‚â•17 
YEARS  OF AGE  ................................................................................................................................. 70  
APPE NDIX 5:  TOLERABILITY ASSESSME NTS ............................................................................. 73  
APPE NDIX 6:  STUDY DRUG APPLICATIO N & SUBJECT I NSTRUCTIO NS ........................... 74  
APPE NDIX 7:  PROTOCOL AME NDME NTS .................................................................................... 77  
 
 
Sofpi[INVESTIGATOR_563575]-4000- CL-302/03 Page 8 of 102 
CONFIDE NTIAL       06 AUG 2020  
SYNOPSIS  
Protocol Title  
A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy 
of Topi[INVESTIGATOR_563576], 15% in Subjects with Axillary Hyperhidrosis (the ‚ÄúCardigan 
II Study ‚Äù) 
Study Objectives  
‚Ä¢To evaluate the safety and local tolerability of  sofpi[INVESTIGATOR_519654], 15% when applied topi[INVESTIGATOR_563577].
‚Ä¢To evaluate the effect of sofpi[INVESTIGATOR_519654], 15 % on hyperhidrosis disease severity as it  relates
to sweat production, patient-reported outcomes, and quality of life self- assessments.
Study Population  
Subjects aged ¬ï[ADDRESS_740447] fulfill all the following criteria to be eligible for study admission: 
1.0DOHRUIHPDOHVXEMHFW¬ï 9 years of age in good general health.
2.Diagnosis of primary axillary hyperhidrosis in the opi[INVESTIGATOR_563578]:
a. Hyperhidrosis Disease Severity Measure -Axilla ry (HDSM -Ax 7-Item1 [HDSM -Ax-7]) of 3 ‚Äì 4
inclusive at both of the Screening Visits (Visits 1 and 4).
b.Gravimetric test indicating a minimum of [ADDRESS_740448] 150 mg of sweat pro duction in five (5) minutes at room
temperature, 20 ¬∞C to 25¬∞ C (68 ¬∞F to 77¬∞ F), at Screening Visit [ADDRESS_740449] one of Visits 2, 3,
or 4.
c.Symptoms of axillary hyperhidrosis for ‚â•6 months‚Äô duration.
3. The ability to understand and sign a written informed consent form (ICF), which must be obtained
prior to any study -related procedures (including medication wash-out, if required) and treatment.
Subjects less than the age of consent must sign an assent for  the study, and a parent or a legal guardian
must sign the informed consent form  (if the subject reaches the age of consent during the study, they
should be re-consented at the next study visit).
4. The ability to understand and sign a Health Insurance Portab ility and Accountability Act (HIPAA)
authorization form, which shall permit the use and disclosure of the subject‚Äôs individually identifiable
health information.5.The ability to understand and follow all study-related procedures including study drug administration.[ADDRESS_740450] 5 items in Section 2 (7 sub -items total) will be used.  The mean will be derived by [CONTACT_563639] 7 
item scores by 7. For each of the 7 sub -items, missing values at EOT will be imputed. HDSM -Ax-7 at EOT will be derived from the 
imputed values.  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 9 of 102 
CONFIDE NTIAL                06 AUG 2020  
6. Sexually active females of childbearing potential (FOCBP)* who are engaging in sexual activity that can cause pregnancy must agree to periodic pregnancy testing and use a medically acceptable method 
of contraception for the duration of the study. This includes perimenopausal women who are less than 
[ADDRESS_740451] menses. Acceptable contraceptive methods include the following:  
a. Abstinence for the duration of the study, or where partner is sterile (e.g., vasectomy); OR 
b. Hormonal contraception, including oral, injectable, or implantable methods started ‚â•2 months 
prior to screening; OR 
c. Non-hormonal contraception, including intrauterine devices ( ‚â•1-week status post placement), 
or properly used barrier methods (e.g., male or female condoms with or without spermicide, 
cervical cap/diaphragm  with spermicid e). 
* FOCBP for this study includes any premenopausal female capable of becoming pregnant 
who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation 
[‚â•6 months prior to baseline] or bilateral oophorectomy) or is not postmenopausal (defined as 
amenorrhea ¬ï12 consecutive months).  
Exclusion Criteria  
The following criteria will exclude a subject from participating in this study: 
1. In the Investigator‚Äôs opi[INVESTIGATOR_1649], diagnosis of any skin or subcutaneous tissue conditions of the axilla(e), 
(i.e., the axillary area should be deemed otherwise ‚Äúnormal‚Äù, besides the hyperhidrosis diagnosis, and 
free of blisters, large boils or sinus tracts, significant scarring , or open wounds). 
2. Prior use of any prohibited medication(s) or procedure(s) for the treatment of axillary hyperhidrosis 
within the specified timeframe:  
a. Botulinum toxin to the axillary area within 9 months of GSP1 (Visit 2).  
b. Prior treatm ent with axillary iontophoresis within 4 weeks of GSP1 (Visit 2). 
c. Axillary thermolysis, sympathectomy, or any other treatment with a medical device or surgical 
procedure of the axillary area at any time in the past. Prior axillary laser hair removal is 
permitted if more than 28 days prior to GSP1 (Visit 2).  
d. Serotonergic agonist (or drugs that increase serotonin activity including selective serotonin re -
uptake inhibitors [SSRIs]), beta -blocker, alpha- adrenergic agonist (clonidine), dopamine partial 
agonist, or tricyclic antidepressant treatment within 28 days of GSP1  (Visit 2). However, a 
subject who has been on a stable dose (in the opi[INVESTIGATOR_1237]) of any of 
these medications and has not had a recent change in hyperhidrosis frequency o r severity for 
3 months prior to the baseline visit may be included. Doses of these agents should not be 
altered during the course of the study. 
e. Any topi[INVESTIGATOR_563579], requiring a prescription, within 28 days of GSP1 
(Visit 2).  
f. Any over-t he-counter topi[INVESTIGATOR_563580]/deodorant (applied directly to the axilla [e]) within 
7 days of GSP1 (Visit 2). Non-antiperspi[INVESTIGATOR_563581]. 
3. Anticholinergic agents used to treat conditions such as, but not limited to, hyperhidrosis, asthma, 
incontinence, gastrointestinal cramps, and muscular spasms by [CONTACT_250112] (e.g., 
intravenous, oral, inhaled, topi[INVESTIGATOR_2855], etc.) within 28 days of GSP1 (Visit 2).  
4. All oral or topi[INVESTIGATOR_563582] (i.e. , alternative therapi[INVESTIGATOR_563583], 
chamomile, valerian root , and St. Jo hn‚Äôs wort) within 28 days of GSP1 (Visit 2).  5. Use of any cholinergic drug (e.g., bethanechol) within 28 days of GSP1 (Visit 2). 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 10 of 102 
CONFIDE NTIAL                06 AUG 2020  
6. Use of any anti-anxiety and/or anti-depressant drugs, psychostimulants (e.g., amphetamine), or drugs with known anticholinergic side effects is prohibited with the following exceptions: 
a. A subject  who has been on a stable dose of an anti -anxiety and/or anti -depressant drug and has 
not had a recent change in hyperhidrosis frequency or severity for ‚â•3 months may be included. 
b. Psychostimulants may be allowed if the dose has been stable for ‚â•3 months without change in 
hyperhidrosis frequency or severity. 
c. Drugs with kno wn anticholinergic side effects (taken within the last 28 days), including dry 
mouth or blurred vision, may be allowed based on the Principal Investigator‚Äôs assessment. 
NOTE: If anticholinergic side effect(s) are experienced on these medications prior to starting 
study medication, document the side effect(s) and severities in the source document and the 
electronic case report form . The doses of these agents should not be altered during the course 
of the study. 
7. Known cause of hyperhidrosis or known history of a condition that may cause hyperhidrosis 
(i.e., hyperhidrosis secondary to any known cause such as hyperthyroidism, diabetes mellitus, 
medications, etc.).  
8. Subjects with hyperhidrosis symptoms initiated or exacerbated with menopause. 
9. Subjects with unstable type 1 or type 2 diabetes mellitus or thyroid disease, renal impairment, hepatic 
impairment, malignancy, glaucoma, intestinal obstructive or motility disease, obstructive uropathy, 
myasthenia gravis, benign prostatic hyperplasia (BPH), neurological conditions, psychiatric 
conditions, Sj√∂gren‚Äôs syndro me, sicca syndrome, or cardiac abnormalities that may alter normal sweat 
production or may be exacerbated by [CONTACT_563640]‚Äôs opi[INVESTIGATOR_1649]. 
10. Subjects with known hypersensitivity to glycopyrrolate, anticholinergics, or any of the components of 
the topi[INVESTIGATOR_59420].  
11. Subject is pregnant, lactating, or is planning to become pregnant during the study. 
12. Participating in a study or used an investigational drug or device within 28 days prior to GSP1 
(Visit  2). 
13. Any major illness within 2 8 days before the screening examination. 
14. Any other condition including psychiatric illness (depression and/or anxiety) that would interfere with 
study participation and/or evaluation of study endpoints or laboratory abnormality that, in the opi[INVESTIGATOR_18959], would put the subject at unacceptable risk for participation in the study or may 
interfere with the assessments included in the study. 
15. Employees of Brickell Biotech, Inc., the Investigator, or contract research organization (CRO) 
involved in the study, or an immediate family member (partner, offspring, parents, siblings, or sibling‚Äôs offspring) of an employee involved in the study. Study Design  
Approximately 350 subjects, at up to approximately 45 clinical sites  in the U nited S tates, will be randomized 
to receive either sofpi[INVESTIGATOR_519654], 15% or vehicle gel (placebo) in a balanced 1:[ADDRESS_740452] (either sofpi[INVESTIGATOR_563584], 15% or vehicle gel) once 
daily at bedtime to each axilla for 42 consecutive days. 
Gravimetric measurements  of sweat production and patient -reported outcomes HDSM -Ax-7 and Dermatology 
Life Quality Index (DLQI ) (via electronic clinical outco mes assessment [ eCOA ] technology) will be recorded during the study at predefined time points. Patient Global Impression of Severity (PGI-S) will be administered 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 11 of 102 
CONFIDE NTIAL                06 AUG 2020  
with each administration of the HDSM-Ax, and the Patient Global Impression of Change (PGI-C) will be administered at the Day 43 visit (End of Treatment) only. Vital signs, local tolerability assessments, and 
adverse events will be collected at each visit. Blood and urine samples will be collected and analyzed at the 
Screening  Visit and at the End o f Treatment  Visit for routine hematology, chemistry, and urinalysis 
parameters. Urine pregnancy test ing for FOCBP  will be performed at the Screening Visit, Baseline Visit, Visit 
[ADDRESS_740453] over approximately 11 to 15 weeks, depending on when the 
Baseline Visit (treatment) is scheduled after the three  (3) screening period visits: initial screening, GSP1 , and 
GSP2.  Test Product, Dose, and Mode of Administration Either sofpi[INVESTIGATOR_519654], 15%; or vehicle gel (placebo) topi[INVESTIGATOR_563585] -two days followed by a 14-day post- treatment follow -up visit Safety Assessments ‚Ä¢ Physical exam ination  
‚Ä¢ Vital signs  
‚Ä¢ Clinica l laboratory assessments  
‚Ä¢ Urinalysis  
‚Ä¢ Collection of a dverse events  
‚Ä¢ Subject- reported local tolerability assessment s  ‚Ä¢ Investigator-reported local tolerability assessments  Efficacy Assessments The following assessment measures will be conducted to eva luate the efficacy of sofpi[INVESTIGATOR_519654]: 
‚Ä¢ Hyperhidrosis Disease Severity Measurement -Axillary ( HDSM -Ax-7) as measured by [CONTACT_423] (for 
subjects ¬ï12 years of age)  
‚Ä¢ Hyperhidrosis Disease Severity Measurement -Axillary , Child (HDSM -Ax-7, Child ) as measu red by 
[CONTACT_423] (for subjects ¬ï9 to <12 years of age)  
‚Ä¢ Gravimetrically measured sweat production (GSP)  
‚Ä¢ Dermatology Life Quality Index (D LQI) as measured by [CONTACT_423] (for subjects ¬ï17 years of age) 
‚Ä¢ Patient Global Impression Scales *; Severity (PGI -S** ) and Change (PGI-C‚Ä†) 
* These questions will be included in the HDSM -Ax questionnaires  
** Administered as Question #6 of HDSM -Ax at  each assessment   
‚Ä† Administered as Question #7 of HDSM -Ax at the Day 43 visit only 
 
Statistical Methods  
Analysis Populations  
Intent -to-Treat Population  
The Intent- to-Treat (ITT) Population will include all subjects who were randomized. Subjects will be analyzed according to the treatment group to which they were randomized, regardless of post randomization 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 12 of 102 
CONFIDE NTIAL                06 AUG 2020  
protocol deviations, including no treatment or wrong treatment received. Per-Protocol Population  
The Per -Protocol (PP) Population will be a subset of the ITT Population and will include subjects who meet 
the following criteria:  
‚Ä¢ Meets all inclusion/exclusion criteria  
‚Ä¢ Has not taken or applied any interfering concomitant medications 
‚Ä¢ Completed the following visits:  
o Visit 2 GSP 1, and the required GSP data collection  
o Visit 3 GSP 2, and the required GSP data collection  
o Visit 4 (Day 1) Re-screening /Baseline  GSP 3  and HDSM -Ax, and the required GSP and HDSM -
Ax data collection  
o Visit 10 (GSP 4) Day 41 (¬± 2 days), and the required GSP data collection  
o Visit 11  (GSP 5) Day 42 (¬± 2 days), and the required GSP data collection  
o Visit 1 2 (GSP 6) Day 43 (¬± 2 days) and HDSM -Ax, and the required GSP and HDSM -Ax data 
collection  
Safety Population 
The Safety Population will include all subjects randomized in the study who received study drug at least once. 
Subjects will be analyzed according to the treatment actually received. If a subject receive s any sofpi[INVESTIGATOR_519670], 15% , the subject  will be analyzed  in the sofpi[INVESTIGATOR_563586]. O therwise , the subject 
will be included in the vehicle group. 
Efficacy  
Co-Primary Efficacy Endpoints : 
‚Ä¢ The proportion of subjects achieving at least a 2- point improvement in the HDSM- Ax-7 scale score 
from baseline to end of treatment ( EOT ). 
‚Ä¢ The change in GSP from baseline to EOT. 
Primary Efficacy Analyses : 
The primary efficacy analy sis will be performed on the ITT  population. Both comparisons will be conducted 
using two-sided tests at an alpha=0.05 level. Both endpoints will need to demonstrate a statistically  significant 
positive result in favor of the sofpi[INVESTIGATOR_519654], 15% for the study to be considered su ccessful.   
The HDSM -Ax-7 co-primary endpoint will be analyzed using a logistic regression  model with the following 
covariates: treatment , baseline HDSM -Ax-7 total score , and analysis center . 
The GSP co -primary endpoint will be analyzed using an analysis of c ovariance (ANCOVA)  model with  fixed 
effects for treatment , baseline ranked GSP, and analysis center . The ANCOVA may use rank -transformed or 
continuous data, pending the outcome of the Shapi[INVESTIGATOR_563587]. The normality test will be 
performed prior to multiple imputation and separately for each arm. Should the normality assumption be 
violated for either arm, the primary analysis will use rank -transformed GSP data. If the normality assumption 
holds for both arms, the primary analysis will use continuous GSP data. 
 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 13 of 102 
CONFIDE NTIAL                06 AUG 2020  
Methods for handling missing data for the Co-Primary Efficacy Endpoints Before performing the primary analysis for the ITT population, m issing  EOT  HDSM -Ax-7 and GSP values  
for the sofpi[INVESTIGATOR_519654], 15% arm will be imputed for the co-primary efficacy endpoints by [CONTACT_563641] a control-b ased imputation (CBI) model approach. Whereas,  multiple imputations for  
missing  values in the vehicle group will be perform ed assum ing missing at random (MAR). For the GSP 
endp oint in particular , in order to ensure that  the missing data imputation method is robust to outliers, data 
from subject s that meet the criterion for being an outlier will be removed from the imputation sampling 
database  (i.e., the existing vehicle database ).  
Sensitivity Analyses of the Co -Primary Efficacy Endpoints  
To further explore the robustness of the primary analysis results  to different missing data assumptions, 
analyses using t wo more  imputation methods will be performed: a missing data imputed to failure  approach 
for the HDSM -Ax-7 co-primary endpoint, and a tippi[INVESTIGATOR_563588] -AX-7 and GSP co -
primary endpoints. Additionally, the ranked GSP and non- rank transformed  GSP ANCOVA analyses will be 
repeated  without imputing missing da ta, and again  after removing outlier data. To further  support the results 
of the co-primary endpoint HDSM- Ax-7, analysis of the 7 individual items in the scale will be conducted. 
Secondary Efficacy Endpoints: 
‚Ä¢ The proportion of subjects achieving at least a 1-point improvement in the HDSM- Ax-7 scale score 
from baseline to EOT.  
‚Ä¢ The proportion of subjects achieving at least a 2-point improvement in the HDSM- Ax-[ADDRESS_740454] a 70% reduction in GSP from baseline to EOT.  
‚Ä¢ The proportion of subjects achieving at least a 1-point improvement in the HDSM- Ax-[ADDRESS_740455] a 50% reduction in GSP from baseline to EOT.  
A gated , fixed -sequence testing procedure will be used to control the overall familywise error rate for the 
primary and secondary analyses. Testing will be performed first for the two co-primary endpoints. If both null 
hypotheses are rejected at the 2 -sided 0.05 s ignificance level in favor of sofpi[INVESTIGATOR_519654], 15%, 
secondary efficacy endpoints will be tested in the order as specified above. Testing will continue only if all 
previously tested null hypotheses of no difference have been rejected at the 2 -sided  0.05 significance level in 
favor of sofpi[INVESTIGATOR_519654], 15%.   
The secondary efficacy  endpoints will be analyzed using methods similar to what is described for the 
co-primary endpoints.  
Method of Pooling S ites to Generate Analysis Centers  
Subjects from  low enrolling sites will be pooled in order to generate analysis centers.  The minimum number 
of subjects per analysis center is 10. The lowest enrolling site will be combined with the largest enrolling site 
that does not meet the minimum requirement, and then the second lowest enrolling site and the second largest 
enrolling site will be combined, and so on. Further combining will be done until all analysis centers have at 
least [ADDRESS_740456] appropriate HDSM-Ax-7-Item scoring algorithm and to examine internal 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740457] validity (i.e., examination of the magnitude of correlation between the HDSM-Ax total score and key variables such as items 4 and 5 of the HDSM -Ax-7-Item, PG I-S, PGI -C, and GSP), stability, 
reliability, ability to detect change, and interpretability of clinical trial results.  
Safety  
Safety analysis will be performed by [CONTACT_563642]. Treatment -emergent 
adverse event (TEAE) descri ptions will be mapped to standard terms, i.e., Medical Dictionary for Regulatory 
Activities ( MedDRA ) system organ c lass and preferred term. At each post -baseline visit, the number and 
proportion of subjects reporting any given TEAE will be tabulated cumula tively  by [CONTACT_926]; each subject will 
be counted only once according to the worst severity reported up to the current visit. Separate tables will be 
constructed for (a) all reported TEAEs, (b) protocol treatment -related TEAEs, (c)  serious TEAEs, (d) TEAEs 
leading to protocol treatment discontinuation , (e) protocol treatment -related serious TEAEs, (f) severe 
TEAEs, (g) TEAEs leading to dose interruption, (h) TEAEs of special interest, and (i) anticholinergic TEAEs .   At each visit, local tolerability assessments  will be descriptively summarized by [CONTACT_926]. An overall summary 
table will also be presented with subject incidences tabulated according to the worst severity experienced 
while on study. In addition, a t each post -baseline visit, local tolerabi lity will be summarized as cumulative 
shift tables versus  baseline. Subject counts for each symptom will be cross- tabulated with baseline severity 
according to the maximum post- baseline severity reported for either axilla up to the current visit.  
Laborator y parameters will be descriptively summarized (mean, standard deviation , median, minimum, 
maximum) for values obtained at Visit 1 and Visit 12 .  Whereas, vital signs will be summarized in a similar 
manner at each visit.   
Sample Size and Power Estimation  
Sample size estimation was performed for the co -primary efficacy endpoints based on the results of a 
Phase  2b study ( BBI-4000- CL-203): 
‚Ä¢ HDSM -Ax-7 responder analysis: 2-point improvement response rates of 29.8% and 53.7% were 
assumed for the vehicle and sofpi[INVESTIGATOR_519654], 15% arms , respectively. The power is 0.95 with 
116 subjects per arm and a total of 232 subjects. 
‚Ä¢ GSP: using rank transformed GSP data for change from baseline to EOT, a difference of 16.6 in mean 
ranks between the vehicle and sofpi[INVESTIGATOR_519654], 15% arms, with a pooled standard deviation 
of approximately 39.5, was used for this purpose. Normal approximation yielded a sample size 
estimate of [ADDRESS_740458] (two -sided p < 0.05) for both co-
primary efficacy endpoints simultaneously is greater than 0.90 (with greater than 0.95 power for each of 
HDSM -Ax-7 and GSP). 
Additionally, sample size estimation was also performed using non-rank-transformed GSP data. An expected 
mean treatment difference  of [ADDRESS_740459] deviation of approximately 170 was used for this 
purpose. This yielded a reduced sample size estimate compared with the target of 300 subjects completing the co-primary efficacy assessments in order to achieve 0.95 power for GSP, further indicating that our sample 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 15 of 102 
CONFIDE NTIAL                06 AUG 2020  
size estimations are conservative. Assuming missing data from approximately 15% of subjects, a total of 350 subjects will be targeted for 
enrollment. 
 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740460] 
HR Heart rate  
ICF Informed consent form 
ICH International Co uncil for Harmonisation  
I/E Inclusion/exclusion 
IEC Institutional Ethics Committee  
IRT Interactive Response Technology  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740461]  squares  
MAR  Missing at random  
MCH  Mean corpuscular hemoglobin  
MCHC  Mean corpuscular hemoglobin concentration 
MCV  Mean corpuscular volume  
MedDRA  Medical Dictionary for Regulatory Activities  
MI Multiple imputation  
MNAR  Missing not at random 
NF National F ormulary  
PGI-C Patient Global Impression of Change  
PGI-S Patient Global Impression of Severity  
PK Pharmacokinetic(s) 
PT Preferred term  
RBC  Red blood cell 
REML  Restricted maximum likelihood  
SAE  Serious adverse event  
SAP Statistical analysis plan 
SAR  Suspected adverse reaction  
SOC  System organ class  
SSRI  Selective serotonin re-uptake inhibitor 
TEAE  Treatment -emergent adverse event  
UPT  Urine pregnancy t est 
US [LOCATION_002]  
USP [LOCATION_002] Pharmacopeia  
WBC  White blood cell 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 18 of 102 
CONFIDE NTIAL                06 AUG 2020  
1 BACKGROU ND AND CLI NICAL RATIO NALE  
Hyperhidrosis is a disorder of excessive sweating beyond what is expected for thermoregulatory needs and 
environmental conditions. Primary hyperhidrosis (excessive sweating without an alternative origin) is localized, 
characteristically symmetric, and may involve several anatomic areas such as  armpi[INVESTIGATOR_10022], hands, and feet. It affects 
approximately 4.8% of the [LOCATION_002]  (US) population ( Doolittle , 2016 ) and is believed to be caused by [CONTACT_563643]. Current therapi[INVESTIGATOR_563589], significant side 
effects, and/or are invasive and costly.  
Oral and topi[INVESTIGATOR_563590], such as glycopyrrolate, have been used to treat hyperhidrosis. The main 
limitations of these drugs are systemic anticholinergic side effects (e.g. , blurred vision, dizziness, dry mouth, 
constipation, urinary retention, and tachycardia). Sofpi[INVESTIGATOR_563591] a novel, soft- anticholinergic ester 
analog of glycopyrrolate and is  in development for the topi[INVESTIGATOR_563592].  
Sofpi[INVESTIGATOR_563591] a competitive inhibitor of acetylcholine receptors located on certain peripheral tiss ues, 
including sweat glands. Sofpi[INVESTIGATOR_563593], thereby [CONTACT_563644], and as a soft drug, is designed to provide maximal therapeutic 
effect with minimal side effect s. Please refer to the sofpi[INVESTIGATOR_563594]‚Äôs Brochure for more 
information. 
In the current multicenter, randomized, double-blinded, vehicle-controlled, pi[INVESTIGATOR_22735], Phase 3 study, Brickell is 
studying the safety, tolerability, and efficacy of topi[INVESTIGATOR_519658], 15%, in subjects with 
primary axillary hyperhidrosis over a 6-week period, followed by a 2-week follow-up period.  
Nonclinical Safety Conclusions  
A comprehensive battery of pharmacology, safety pharmacology, absorption, distribution, metabolism, excretion 
(ADME) , acute to chronic toxicity, genotoxicity, carcinogenicity (ongoing), and reproductive toxicity evaluations 
has been conducted to evaluate the safety of sofpi[INVESTIGATOR_563595]. 
Overall, the results of the nonclinical program support the safe use of sofpi[INVESTIGATOR_563596]. Please refer to the sofpi[INVESTIGATOR_563597]‚Äôs Brochure for additional information pertaining to the nonclinical studies. 
Prior Human Experience  
Brickell  and its  partner company ( Kaken Pharmaceutical , Japan ) have conducted multiple  clinical  studies of 
sofpi[INVESTIGATOR_563598] [ADDRESS_740462] evaluated the safety, 
tolerability, pharmacokinetics ( PK), and efficacy of sofpi[INVESTIGATOR_563599]. Please refer to the sofpi[INVESTIGATOR_563600]‚Äôs 
Brochure for more detailed descriptions and results of the clinical studies.  
Clinical Safety Conclusions   
In studies conducted to date, t hree concentrations  of sofpi[INVESTIGATOR_519654], 5%, 10%, and 15%, demonstrated 
comparably acceptable safety and tolerability. Treatment- emergent adverse events (TEAEs) were mostly mild or 
moderate in severity with fewer subjects reporting TEAEs in the 5% gel group relative to the 10% and 15% gel 
groups. No deaths or drug-related serious adverse reactions have been reported in any sofpi[INVESTIGATOR_563601]. Six serious adverse events have been reported  and all were determined to be unrelated to 
sofpi[INVESTIGATOR_563602]. 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 19 of 102 
CONFIDE NTIAL                06 AUG 2020  
Consistent with the soft drug design, a low incidence of systemic anticholinergic adverse events (AEs)  has been 
found in all clinical studies of sofpi[INVESTIGATOR_519654]. The most common anticholinergic AE was dry mouth, 
and all anticholinergic AEs were expected. Of note, the anticholinergi c AEs were predominantly mild or 
moderate in severity and transient in duration  (i.e., resolving gradually with continued use) . All TEAEs 
completely resolved spontaneously with treatment discontinuation. L ocal application site  tolerability reactions of 
burning, itching, pain, erythema, and dryness at the axillae were predominantly minimal in severity and  typi[INVESTIGATOR_563603].  
Clinical Efficacy Conclusions   
Overall, a ll three sofpi[INVESTIGATOR_563604], 5%, 10%, and 15%, have exhibited a large r absolute 
mean reduction in gravimetric sweat production (GSP) from baseline to end of treatment (EOT) compared with 
vehicle. Better improvement in GSP response was associated with higher concentrations of sofpi[INVESTIGATOR_519666]. 
However, while there was a slight trend toward dose response, all gel concentrations were essentially equivalent 
in patient- reported outcome measures based on the Hyperhidrosis Disease Severity Measure -Axillary 
(HDSM -Ax), Dermatology Quality of Life Index ( DLQI ), and Hyperhidrosis Di sease Severity Score (HDSS) , 
suggesting that all three concentrations are efficacious. The response was seen as early as Day 8 and remained 
consistent throughout the applicable treatment period. 
Clinical Pharmacokinetics  Conclusions   
In PK studies conducted to date,  both sofpi[INVESTIGATOR_563605]-4010 could be measured  in the 
majority of subjects. Systemic exposure to sofpi[INVESTIGATOR_519665]-4010 appeared to increase in an approximately 
dose-proportional manner when comparing the 5% and 15% gel concentrations, indicating that applying a more 
concentrated gel increased exposure. However, inter- subject variability of PK parameters was extremely high. 
Absorption is thought to be affected by [CONTACT_563645], temperature, hydration, and degree of occlusion.  
Systemic exposure of sofpi[INVESTIGATOR_519665]-[ADDRESS_740463] dose (Day 1) and also 
after multiple doses (Day 21). Sofpi[INVESTIGATOR_563606] [ADDRESS_740464] samples analyzed were below 
1 ng/mL, with many below the lower limit of quantification of 0.05 ng/mL for both sofpi[INVESTIGATOR_519665]-4010.  
Risk to Subjects   
As an anticholinergic drug, administration of sofpi[INVESTIGATOR_563607], blurred vision, dizziness, constipation, urinary 
retention, or tachycardia. The previous sofpi[INVESTIGATOR_563608] a low 
incidence of these effects, which are generally mild in severity. All such effects have been observed, and as 
expected, to be tr ansient.  
2 STUDY DESIG N 
This is a multicenter, randomized, double-blinded, vehicle-controlled, Phase 3 study to evaluate the safety and 
efficacy  of topi[INVESTIGATOR_519658], 15% in subjects with primary axillary hyperhidrosis.  
Approximately 350 subjects , at up to approximately 45 clinical sites  in the US , will be enrolled to obtain 
approximately 300 evaluable  subjects at the end of study. 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 20 of 102 
CONFIDE NTIAL                06 AUG 2020  
Subjects will be randomized 1:1 to receive  sofpi[INVESTIGATOR_519654], 15% or vehicle gel (175 subjects dose d with 
15% gel and 175 subjects dosed with vehicle gel ). Subjects will apply the investigational product once daily at 
bedtime to their axillae for 42 consecutive days. 
Patient -reported outcomes HDSM -Ax, Patient Global Impression of Severity ( PGI-S), Patient Global Impression 
of Change ( PGI-C; EOT only), and DLQI , as well as Investigator -reported GSP, will be recorded during the 
study at predefined time points. Vital signs and local tolerability assessments  will be collected at Visits 4  through 
9 and Visits 12 (EOT) and 13. Adverse events will be collected at each post -Screening visit. Blood and urine 
samples will be collected and analyzed at  Screening and Visit 12 /EOT  for routine hematology, chemistry, and 
urinalysis parameters. Additionally, a urine pregnancy test (UPT) for females of child -bearing potential (FOCBP) 
will be collected and analyzed at Visit s 1, 4, 8, and 12. 
A total of [ADDRESS_740465] over approximately 11 to 15 weeks, depending on when the Baseline 
Visit (trea tment) is scheduled after the three  (3) screening period visits: initial screening, GSP1 , and GSP2 . See 
Section 7.1 for an events table of this study.   
3 STUDY OBJECTIVES A ND ASSESSME NTS 
The purpose of this Phase 3 study is to assess the safety , local tolerability , and efficacy of sofpi[INVESTIGATOR_519673], 15% when applied topi[INVESTIGATOR_563609].  
3.1 Study Objectives  
‚Ä¢ To evaluate the safety and local tolerability of sofpi[INVESTIGATOR_519654], 15% when applied topi[INVESTIGATOR_563610].  
‚Ä¢ To evaluate the effect of sofpi[INVESTIGATOR_519654], 15% on hyperhidrosis disease severity as it relates to  
sweat production, patient-reported outcomes, and quality of life self- assessments . 
3.2 Study Assessments  
Safety Measures:  
The following safety assessment measures will be conducted to evaluate the safety and local tolerability of 
sofpi[INVESTIGATOR_519654], 15%: 
‚Ä¢ Physical exam ination  
‚Ä¢ Vital signs  
‚Ä¢ Clinical laboratory assessments  
‚Ä¢ Urinalysis  
‚Ä¢ Collection of AEs 
‚Ä¢ Subject- reported local tolerability assessment s 
‚Ä¢ Investigator- reported local tolerability assessment s 
Efficacy Assessments:  
The following assessment measures will  be con ducted to evaluate the  efficacy of sofpi[INVESTIGATOR_519654], 15%: 
‚Ä¢ HDSM -Ax 7-Item (HDSM -Ax-7) as measured by [CONTACT_423]  (for subjects ¬ï12 years of age) 
‚Ä¢ Hyperhidrosis Disease Severity Measurement -Axillary , Child (HDSM -Ax-7, Child ) as measured by [CONTACT_1560] (for subjects ¬ï9 to <12 years of age)  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 21 of 102 
CONFIDE NTIAL                06 AUG 2020  
‚Ä¢ GSP 
‚Ä¢ DLQI as measured by [CONTACT_563646] ¬ï17 years of age 
‚Ä¢ Patient Global Impression Scales * - Severity (PGI -S**) and Change (PGI-C‚Ä†) 
* These questions will be included in the HDSM -Ax questionnaires  
** Administered as Question #6 of HDSM -Ax at  each assessment   
‚Ä† Administered as Question #7 of HDSM -Ax at the Day 43 visit only 
 
4 STUDY POPULATIO N 
4.1 Number of Subjects  
Approximately 350 subjects, at  up to approximately 45 clinical sites, will be randomized to receive either 
sofpi[INVESTIGATOR_519654], 15% or vehicle gel in a 1:[ADDRESS_740466] fulfill all of the following criteria to b e eligible for study admission: 
1. 0DOHRUIHPDOHVXEMHFW¬ï 9 years of age in good general health. 
2. Diagnosis of primary axillary hyperhidrosis in the opi[INVESTIGATOR_563611]:  
a. HDSM -Ax-72 of 3-4 inclusive at both of the Screening visits (Visits 1 and 4) 
b. Gravimetric test indicating a minimum of [ADDRESS_740467] 150 mg of sweat production in five (5) minutes at room 
temperature , 20¬∞C to 25¬∞ C (68¬∞F to 77¬∞ F), at Screening Visit [ADDRESS_740468] one of Visits 2, 3, or 4 
c. Symptoms of axillary hyperhidrosis for ‚â•6 months‚Äô duration 
3. The ability to understand and sign a written informed consent form (ICF), which must be obtained prior to 
any study- related procedures (including medication wash -out, if required) and treatment. Subjects less 
than the age of consent must sign an assent for the study, and a parent or a legal guardian must sign the 
informed consent form (if the subject reaches the age of consent during the study, they should be re-
consented at the next study visit). 
4. The ability to understand and sign a Health Insurance Portability and Accountability Act (HIPAA) 
authorization form, which shall permit the use and disclosure of the subject‚Äôs individually identifiable 
health information.  
5. The ability to understand and follow all study-related procedures including study drug administration.  
6. Sexually active female s of childbearing potent ial (FOCBP) * who are engaging in sexual activity that can 
cause pregnancy   must agree to periodic pregnancy testing and use a medically acceptable method of 
                                                 
[ADDRESS_740469] 5 items in Section 2 (7 sub -items total) will be used.  The mean will be derived by [CONTACT_563647] [ADDRESS_740470] answer all of the 7 sub -items to be evaluable for the HDSM -Ax-7 scale assessment.  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740471] menses. Acceptable contraceptive methods include the following:  
a. Abstinence for the duration of the study, or where partner is sterile (e.g., vasectomy); OR 
b. Hormonal contraception, including oral, injectable, or implantable methods started ‚â•2 months 
prior to screening ; OR 
c. Non-hormonal contraception, including intrauterine devices ( IUD; ‚â•[ADDRESS_740472] 
placement), or properly used barrier methods (e.g., male or female condoms with or without 
spermic ide, cervical cap/diaphragm  with spermicide) .  
*  FOCBP  for this study include s any premenopausal female capable of becoming pregnant who has 
not undergone successful surgical sterilization  (hysterectomy, bilateral tubal ligation [‚â•6 months prior 
to baseline] or bilateral oophorecto my) or is not postmenopausal (defined as amenorrhea 
¬ï12 consecutive  months).  
4.[ADDRESS_740473] from participating in this study : 
1. In the Inve stigator ‚Äôs opi[INVESTIGATOR_1649], diagnosis of any skin or subcutaneous tissue conditions of the axilla(e), (i.e., 
the axillary area should be deemed otherwise ‚Äúnormal‚Äù, besides the hyperhidrosis diagnosis, and free of 
blisters, boils or sinus tracts, significant scarring , or open wounds). 
2. Prior use of any prohibi ted medication(s) or procedure(s) for the treatment of axillary hyperhidrosis  
within the specified timeframe : 
a. Botulinum tox in to the axillary area within 9  months of GSP1  (Visit 2).  
b. Prior treatment with axillary iontophoresis within 4 weeks of GSP1 (Visit 2) 
c. Axillary thermolysis, sympathectomy, or any other treatment with a medical device  or surgical 
procedure of the axillary area at any time in the past. Prior axillary laser hair removal is permitted 
if more than 28 days prior to GSP1 (Visit 2).  
d. Serotonerg ic agonist (or drugs that increase serotonin activity including selective serotonin 
re-uptake inhibitors [ SSRIs ]), beta- blocker, alpha -adrenergic agonist (clonidine), dopamine partial 
agonist, or tricyclic antidepressant treatment within 28 days of GSP1  (Visit 2). However, a subject 
who has been on a stable dose (in the opi[INVESTIGATOR_2511] P rincipal Investigator) of any of these 
medications and has not had a recent change in hyperhidrosis frequency or severity for 3 months 
prior to the baselin e visit may be included. Doses of these agents should not be altered during the 
course of the study. 
e. Any topi[INVESTIGATOR_563579] , requiring a prescription , within 28 days of GSP1 
(Visit  2). 
f. Any over- the-counter topi[INVESTIGATOR_563580]/deodorant (applied directl y to the axilla [e]) within 
7 days of GSP1 (Visit 2).  Non-antiperspi[INVESTIGATOR_563581]. 
3. Anticholinergic agents  used to treat conditions such as , but not limited to,  hyperhidrosis, asthma, 
incontinence, gastrointestinal cramps, an d muscular spasms  by [CONTACT_563648] (e.g., 
intravenous [IV] , oral, inhaled, topi[INVESTIGATOR_2855], etc. ) within 28 days of GSP1  (Visit 2).   
4. All oral or topi[INVESTIGATOR_563582] (i.e., alternative therapi[INVESTIGATOR_563583], 
chamomile, valerian root , and St. John‚Äôs w ort) within 28 days of GSP1  (Visit 2).  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 23 of 102 
CONFIDE NTIAL                06 AUG 2020  
5. Use of any cholinergic drug (e.g., bethanechol) within 28 days of GSP1  (Visit 2).  
6. Use of any anti-anxiety and/or antidepressant drugs, psychostimulants (e.g., amphetamine), or drugs with 
known anticholinergic side effects is prohibited with the following exceptions: 
a. A subject who has been on a stable dose of an anti -anxiety and/or antidepressant drug and has not 
had a recent change in hyperhidrosis frequency or severity for ¬ï3 months may be included.   
b. Psychostimulants may be allowed if the dose has been stable for  ¬ï3 months without change in 
hyperhidrosis frequency or severity. 
c. Drugs with known anticholinergic side effects (taken within the last 28 days) including dry mouth 
or blurred vision may be allowed based on the Investigator ‚Äôs assessment.  
NOTE: If anticholinergic side effect(s) are experienced on these medications prior to starting study 
medication , document the side effect(s) and severities in the source document and the electronic case 
report form ( eCRF ). The doses of these agents should not be altered during the course of the study. 
7. Known cause of hyperhidrosis or known history of a condition that may cause hyperhidrosis 
(i.e., hyperhidrosis secondary to any known cause such as hyperthyroidism, diabetes mellitus, 
medications, etc.).  
8. Subjects with hyperhidrosis symptoms initiated or exacerbated with menopause. 
9. Subjects with  unstable type 1 or type 2 diabetes mellitus or thyroid disease, renal impairment, hepatic 
impairment, malignancy, glaucoma, intestinal obstructive or motility disease, obstructive uropathy, 
myasthenia gravis, benign prostatic hyperplasia (BPH), neurologic al conditions, psychiatric conditions, 
Sj√∂gren‚Äôs syndrome, sicca syndrome, or cardiac abnormalities that may alter normal sweat production or 
may be exacerbated by [CONTACT_563640]‚Äôs opi[INVESTIGATOR_1649]. 
10. Subjects with known hypersensitivity to glycopyrrolate, anticholinergics, or any of the components of the 
topi[INVESTIGATOR_59420]. 
11. Subject is pregnant, lactating, or is planning to become pregnant during the study.  
12. Participating in a study or used an investigational drug or devi ce within 28 days prior to GSP1 (Visit 2).  
13. Any major illness within 28 days before the screening examination. 
14. Any other condition, including psychiatric illness (depression and/or anxiety) that would interfere with 
study participation and/or evaluation of study endpoints or laboratory abnormality that, in the opi[INVESTIGATOR_15960], would put the subject at unacceptable risk for participation in the study or may interfere 
with the assessments included in the study. 
15. Employees of Brickell Biotech, Inc., the Investigator, or contract research organization (CRO) involved in 
the study, or an immediate family member (partner, offspring, parents, siblings, or sibling‚Äôs offspring) of 
an employee involved in the study. 
 
[ADDRESS_740474]  (IP) 
Sofpi[INVESTIGATOR_563612] a gel base comprising 
hydroxypropyl cellulose National Formulary ( NF), hexylene glycol NF, isopropyl myristate NF, citric acid 
anhydrous [LOCATION_002] Pharmacopeia ( USP), and alcohol dehydrated USP . Sofpi[INVESTIGATOR_519666] g el is a clear 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 24 of 102 
CONFIDE NTIAL                06 AUG 2020  
to slightly translucent colorless gel and is packaged in a white -colored, metered pump container. One pump 
container is packaged in a carton  with 2 applicators. The total gel volum e in each  pump  container is ~50 mL 
(~43 g). The gross weight of each full container at baseline is approximately 78 to 84 grams.  
Based on one full pump actuation delivering ~0.67 mL of the gel formulation, a total of approximately 38 mL of 
gel is required for 4 weeks (28 days) of daily dosing to the axillae . Ther efore, each pump  container is sufficient 
for ‚â•[ADDRESS_740475] at Baseline  
(Visit 4) and  Day 22 (Visit 7).  
5.[ADDRESS_740476] should be stored at controlled room  temperature  68oF to 77oF (20oC to 25oC) with brief 
excursions permitted between 59¬∞F to 86¬∞F (15oC to 30oC). Maintenance of a temperature log (manual or 
automated) is required.   
5.[ADDRESS_740477] will be randomized  via an Interactive Response Technology (IRT) system to  receive either 
sofpi[INVESTIGATOR_519654], 15%, or vehicle gel (placebo) to topi[INVESTIGATOR_563613], once daily at b edtime, to each axilla 
using the supplied applicators for [ADDRESS_740478] to each axilla using all the gel expressed from 
one full actuation  of the pump per each axilla dose application. Each  full actuation of the pump corresponds to 
approximately 86.5 mg of sofpi[INVESTIGATOR_563614] 15% investigational product.   
The subject will apply all doses of investigational product at night, prior to going to bed, using the supplied 
applicators. Subjects will apply their first dose of gel prior to bedtime on the night of their Baseline Visit. The 
subject will be instructed to continue applying the investigational product each night with the last application to 
occur the night before attending the end of treatment evaluation (i.e., V isit 12). Subjects should wash the 
applicator each night after dosing. Two applicators are provided in each kit to compensate for loss or damage 
during handling; it is not necessary to use all the applicators over the specified dosing interval. 
To ensure accurate dosing, the study s taff will be instructed to first prime and then weigh each pump container 
before dispensing to the subject. Priming is accomplished by [CONTACT_563649] (5) sequential 
actuations; the dispensed gel from these [ADDRESS_740479]. Over the course of the study, a container will be primed, 
weighed, and dispensed at both the Baseline Visit ( Visit 4, Day 1) and Visit 7 (Day 22) for a total of 2 cont ainers  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740480] at a next respective visit  
(Visit 7 and Visit 12  [EOT] ), weighed with the cap on, and weight recorded per the unique bottle number. At the 
End of Treatment visi t (Visit  12), the subject will bring the 2nd container to his/her visit for the final weight 
determination ; however, no additional investigational product will be dispensed. Study subjects may return the 
applicators, or they may discard them after dosing i s completed.  
At each visit, gel application instructions and compliance will be discussed and documented.  
5.[ADDRESS_740481] every day, at night prior to bedtime, using a 
supplied applicator  as follows (a written instruction sheet  and access to a study product application video and 
digital mobile application  will be supplied to the subject): 
1. Expose the underarm areas and ensure they are dry. Do not wash the underarm areas for at least [ADDRESS_740482] to dry for 5 minutes before putting any clothes on the upper body. 
Important information:  
‚Ä¢ The subject should sleep in a T-shirt or similar pajama to avoid touching the underarm area while sleepi[INVESTIGATOR_007]. 
‚Ä¢ Subjects should maintain their underarm grooming habits as follows: 
o Do not shower, shave, or wash the underarm area for at least [ADDRESS_740483]. 
‚Ä¢ Subjects should not apply any other product to the axillary area (including the supplied non-antiperspi[INVESTIGATOR_563615]) for at least [ADDRESS_740484] application.  
‚Ä¢ The subject should use the applicator provided to avoid contact [CONTACT_563650]. Special care should be 
taken to avoid contact [CONTACT_519713]. Of note, hands should be washed after applying the 
gel to avoid possible skin and eye contact [CONTACT_563651]. 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 26 of 102 
CONFIDE NTIAL                06 AUG 2020  
‚Ä¢ The study product contains alcohol and is flammable. The subject should avoid fire, flames,  or smoking 
during the application and until the gel has dried. The subject should not expose t he container to fire, flame s, 
or extreme heat.  
On the day of a clinic study visit:  
‚Ä¢ Showering and shaving  in the morning is permissible. 
‚Ä¢ Do not apply any product to the axilla (including S ponsor-supplied non-antiperspi[INVESTIGATOR_563616]). 
‚Ä¢ Exercise is to be avoided (e.g., gym, jogging, etc.). 
‚Ä¢ Avoid caffeine and tea until the gravimetric assessments are completed.  
5.4 Procedures for Blinding and Unblinding  
This is a double-blind study. All study treatme nts (sofpi[INVESTIGATOR_519654], 15%, and vehicle gel) are identi cal in 
color, shape, size, and packaging in order to maintain the blind.  
Subjects, Sponsor personnel, Investigator staff, persons performing the assessments, clinical operations personnel, 
data analysts, and personnel at central laboratories will remain b linded to the identity of the treatment from the time of 
randomization until database lock and unblinding, using the following methods: (1) randomization data will be 
maintained by a third party, kept strictly confidential until the time of unblinding, and will not be accessible by [CONTACT_563652]; (2) the identity of the treatments will be concealed by [CONTACT_563653], labeling, schedule of administration, and appearance. 
The treatment assignments for all enrolled subjects will be unblinded only after the conclusion of the study. 
Specifically, the blind will be broken only after all data are verified, entered into the database, and validated ; subject  
evaluability assessments are performed and entered into the database; and the database is locked.  In the case of a  
medical emergency, the Investigator can break the blind for the subject involved preferably by [CONTACT_563654] (or designee) immediately. After confirmation, the Investigator 
will be contact[CONTACT_85193] a Sponsor representative. The Investigator will record the code break 
in the  subject‚Äôs source documents. 
6 CONCOMITA NT MEDICATI ONS/TREATME NTS 
Information  will be recorded  on concomitant medications/treatments (e.g., aspi[INVESTIGATOR_248], Tylenol, birth control pi[INVESTIGATOR_3353], 
intrauterine device  [IUD], vitamins) taken during study participation, or which may require a washout for study 
participation. Every effort should be made to keep dosing with any concomitant medications consistent/ constant 
during the study.  
6.1 Permissible Medications/Treatments  
Therapy considered necessary for the subject's welfare may be given at the discretion of the I nvestigator. If the 
permissibility of a specific medication/treatment is in question, the M edical Monitor should be contact[INVESTIGATOR_530]. 
Subjects will be instructed to not apply any contraindicated topi[INVESTIGATOR_563617] (see list in 
Section 6.2). The Sponsor-supplied non-antiperspi[INVESTIGATOR_563618] [ADDRESS_740485] (suggest applying in the morning). 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 27 of 102 
CONFIDE NTIAL                06 AUG 2020  
6.2 Prohibited Medications/Treatments  
The decision to administer a prohibited medication/treatment  is made with the safety of the study participant as 
the primary consideration. When possible, Brickell Biotech‚Äô s Medical Monitor should be notified before a 
prohibited medication/treatment is administered.  
Prior to the inclusion of a subject in the study, as specified in  Sections 4.2 and 4.3 (inclusion/ exclusion  criteria), 
and throughout the duration of the study, the use of the following medications/treatments is prohibited: 
‚Ä¢ Anticholinergic agents  used to treat conditions such as , but not limited to,  hyperhidrosis, asthma, 
incontinence, gastrointestinal cramps, and muscular spasms by [CONTACT_250112] (e .g., IV, oral, 
inhaled, topi[INVESTIGATOR_563619] ). 
 
‚Ä¢ Any oral or topi[INVESTIGATOR_563582] (i.e. , alternative therapi[INVESTIGATOR_563583], 
chamomile, valerian root , and St. John‚Äôs wo rt). 
‚Ä¢ Any prescription topi[INVESTIGATOR_49186], including topi[INVESTIGATOR_563620] (e.g., 
Drysol, Xerac AC, Certain DRI) and hand sanitizers applied to the axillae for the duration of the study.      
‚Ä¢ Any treatment or procedure for axillary  hyperhidrosis including but not limited to: 
o botulinum toxin  
o thermolysis treatments including microwave (e.g. , MiraDry ), laser , or other (s)  
o sympathectomy 
o iontophoresis 
‚Ä¢ Any surgical procedure involving the axillae  (including laser hair removal), or any surgi cal procedures that 
will result in significant scarring of the axillae . 
‚Ä¢ Any oral cholinergic ( e.g., bethanechol) throughout the duration of the study. 
‚Ä¢ Addition of, or change of dose  for any medication that is allowed as specified in Sections 4.2 and 4.3 
(inclusion/exclusion  criter ia) including the following:  
o serotonergic agonists (or drugs that increase serotonin activity including SSRIs)  
o beta-blockers  
o alpha- adrenergic agonist s (clonidine)  
o dopamine partial agonists  
o tricyclic antidepressants  
o anti-anxiety and/or other anti -depressant drugs  
o amphetamine products 
o drugs with known anticholinergic side effects. 
7 PROCEDURES  
The timing of each assessment is listed in the Time and Events Table ( Section 7.1).   
Each subject will report for [ADDRESS_740486] visits  (over  11-15 weeks).  
All Screening assessment results must be completed and reviewed prior to the GSP1  Visit (within 31 days). 
Therefore, none of the Screening Visit  days can occur on the same day as the Baseline Visit.  
Subjects may be consented for up to 31 days before the GSP1  Visit . Subjects outside this screening window shall 
be re-consented and certain screening activities may need to be repeated. Prior to enrollment into the treatment 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740487] the Medical Monitor to address such subjects on a 
case-by-case basis.  
In the event of restrictions due to COVID -19, or any other pandemic, the Sponsor may, with IRB approval where 
required, during the study implement some or all study assessments and procedures associated with patient visits 
to be conducted remotely or by [CONTACT_537141] (per FDA Guidance on Conduct of Clinical Trials of Medical 
Products during COVID-19 Public Health Emergency, March 2020) when the patients‚Äô ability to visit 
investigator sites is impacted.  
 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 29 of 102 
CONFIDE NTIAL                06 AUG 2020  
7.1 Time and Events Table  
Visit  1  2  3  4  5  6  7  8  9  10  11  12  13  
PROCEDURE  Screening 
  Rescreening / Baseline 
       
End of Treatment 
Follow -up 
Gravimetric Timepoint   GSP 
11 GSP 
21 GSP 
31      GSP 
4 GSP 
5 GSP 
6  
Day  (allowable window)  Up to  
 31 days prior to  GSP1     (Day 1) Day   
8   
(¬± 2)  Day  
15   
(¬± 2)  Day  
22   
(¬± 2)  Day  
29   
(¬± 2)  Day  
36   
(¬± 2)  Day  
41   
(¬±2)  Day  
42   
(¬± 2)  Day  
43   
(¬± 2)  Day  
57   
(¬± 3)  
Informed Consent/Assent  X             
Medical History, Demographics  X   X          
Physical Exam     X          
Vital Signs (blood pressure, heart rate, 
respi[INVESTIGATOR_697] , and temperature)     X X X X X X   X X 
I/E Criteria  X   X          
Gravimetric Assessments2,3 X X X X X X X X X X X X X 
HDSM -Ax4,5 X   X X X X X X X X X X 
DLQI6    X  X      X  
Local Tolerability Assessments7    X X X X X X   X X 
Adverse Events   X X X X X X X X X X X X 
Randomization8    X          
Non -antiperspi[INVESTIGATOR_563621]9 X             
Investigational Product10 (IP) Dispensed / 
Returned     X   X       X  
IP Weight11    X   X     X  
Compliance Evaluation      X X X X X X X X  
Safety Labs (hematology, chemistry, and 
urinalysis)  X           X  
UPT (females of childbearing potential 
only)12 X   X    X    X  
Concomitant Medication Review  X X X X X X X X X X X X X 
Optional  End of Study Patient Survey13              X 

Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 30 of 102 
CONFIDE NTIAL                06 AUG 2020  
Abbreviations: DLQI = Dermatology Life Quality Index; FOCBP = females of child -bearing potential; HDSM -Ax = Hyperhidrosis Disease Severity 
Measure -Axillae;  I/E = inclusion/exclusion; IP = investigational product; PGI -C = Patient Global Impression of Change ; PGI -S = Patient Global 
Impression of Severity; UPT = urine pregnancy test  
1 Visit 2 should occur no more than 31 days after the initial screening visit (Visit 1); both Visits 2 and 3 should occur within 14 days of 
rescreening/baseline Visit 4. Visit 4 wi ll correspond to Day 1.  
2 Gravimetric assessments for all visits will be conducted from 7:00am-11:00am .  
3 One 5 -minute gravimetric assessment will be conducted for each axilla.  
4 PGI-S will be administered as Question #6 of HDSM -Ax at every assessment; PGI-C will be administered as Question #7 of HDSM -Ax at the Day 43 
visit only.  
5 Version of HDSM -Ax questionnaire to  EHDGPLQLVWHUHGDFFRUGLQJWRVXEMHFWDJH¬ïWRﬁí\HDUVRU¬ï\HDUVRIDJH . 
6 7KH'/4,ZLOOEHDGPLQLVWHUHGWRVXEMHFWV¬ï\HDUVRID ge. 
[ADDRESS_740488] is qualified at the Rescreening Visit (Visit 4) .   
9 Non-antiperspi[INVESTIGATOR_563622]  (Visit 1) and resupplied as needed throughout the study . 
[ADDRESS_740489] at Baseline (Visit 4). Pump [ADDRESS_740490] at Day 22 (Visit 7) . Written instructions for nightly dosing will be given to the subject. Subjects will apply their first dose of gel prior to 
bedtime the night of their Baseline visit. Instruct the subjects to return Pump  container 1 of 2 at Day 22 (Visit 7) and Pump  container 2 of 2 at 
Day 43 (Visit 12, End of Treatment ).    
[ADDRESS_740491] and upon return at 
Day 22 (Visit 7). Pump container 2 of 2 will be weighed with the applicator cap on after priming at Day 22 (Visit 7) prior to dispensing to the 
subject and upon return at Day 43 (Visit 12, End of Treatment ).    
12 FOCBP for this study includes any premenopausal female capable of becoming pregnant who has not undergone successful s urgical sterilization 
(hysterectomy, bilateral tubal ligation [ ‚â•6 months prior t o baseline] , or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea 
‚â•12 consecutive months).  
13 2SWLRQDOHQGRIVWXG\VXUYH\ZLOOEHRIIHUHGWRVXEMHFWV¬ï\HDUVRIDJH .
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 31 of 102 
CONFIDE NTIAL                06 AUG 2020  
7.2 Visit -Specific Procedures  
7.2.1  Visit 1: Screening (Days -31 to 0) 
Written informed consent must be obtained prior to any study- related procedures. Potential subjects will be 
screened w ithin 45 days prior to Visit 4 (Rescreening/Baseline) to assess their eligibility to enter the study. Only 
eligible subjects with axillary hyperhidrosis will be enrolled.  
After informed consent is obtained, the following procedures will be performed: 
‚Ä¢ Colle ct and review subject medical history and demographics.  
‚Ä¢ Assess inclusion/exclusion criteria.   
‚Ä¢ Subject to complete the GSP assessment.  
o GSP assessments for all visits will be conducted from 7:00 am to 11:00 am . 
o One 5 -minute GSP assessment will be conducted  for each axilla.  
o Refer to Appendix 1  for instructions and requirements of sample collection and handling. 
‚Ä¢ Subject to complete the HDSM -Ax assessment .  
o Five multi -part questions  and PGI-S question ( administered as Question #6  at the end of the 
HDSM -Ax questionnaire ) to be completed by [CONTACT_563655].  
o Refer to Appendix 2  (HDSM -Ax) and Appendix 3  (HDSM -Ax Child ) 
‚Ä¢ Perform UPT if applicable (FOCBP only). If positive, the subject shall be screen failed.   
‚Ä¢ Collect samples for laboratory assessments (hematology, ch emistry , and urinalysis) (see Section 8.1.3 ).  
‚Ä¢ Review concomitant medications/treatments and assess for washouts.  
‚Ä¢ Provide subject with the S ponsor-provided non-antiperspi[INVESTIGATOR_563616]. Resupply as needed throughout 
subject study participation.  
‚Ä¢ Schedule the subject to return for Visit 2 ( GSP1 ) after any washout has been completed; must be within 
31 days of Visit 1 (Screening).  
In the event a subject does not satisfy the sweat production eligibility (Inclusion criteri on 2b) at the Screening 
Visit but is otherwise eligible to continue (i.e., satisfies all other eligibility requirements including HDSM -Ax 
severity but may still require a washout) , the Screening GSP may be retested once during the screening period at 
the discretion of the Investigator:   
‚Ä¢ Retest must occur within the 31 days from Screening (Visit 1) and must occur prior to GSP1 
(Visit  2).   
‚Ä¢ HDSM -Ax must also be completed at the time of the Screening GSP retest.   
‚Ä¢ If subject does n ot meet inclusion based on GSP and HDSM -Ax results at the time of the retest, the 
subject shall be screen failed and may not be rescreened.  
The subject shall be reminded that, on the day of each clinic study visit:   
‚Ä¢ Showering in the morning is permissible.  
‚Ä¢ Do not apply any product to the axilla (including Sponsor-supplied deodorant).  
‚Ä¢ Exercise is to be avoided (e.g., gym, jogging, etc.).  
‚Ä¢ Avoid caffeine and tea until the gravimetric assessments are completed.  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 32 of 102 
CONFIDE NTIAL                06 AUG 2020  
7.2.2  Visit s 2 and 3 : GSP1  and GSP2   
Visit 2 should occur no more than 31 days after the in itial screening visit (Visit 1); both Visits 2 and 3 should 
occur within 14 days of R escreening/ Baseline  Visit 4.  Any washouts required for prohibited medications (s ee 
Section 4.3) must be comp leted prior to Visit 2 (GSP1 ).  
The following activiti es will be conducted:  
‚Ä¢ Subject to complete the GSP assessment; will be conducted from 7:00 am to 11:00 am . 
‚Ä¢ Review the subject‚Äôs health ( AEs). 
‚Ä¢ Review concomitant medications/treatments.  
‚Ä¢ Schedule the subject to return for the next study visit.  
7.2.3  Visit 4: GSP3  (Day 1 ; Rescreening/Baseline ) +14 Days of Visit 2  
No more than 14 days may elapse between Visit 2 (GSP1) and Visit 4 (GSP3 ; Day 1 ).    
The following activities will be conducted:  
‚Ä¢ Collect and review subject medical history and demographics.  
‚Ä¢ Perform physical exam ination  including collection of height and weight (see Section 8.1.1 ). 
‚Ä¢ Collect vital signs (blood pressure, heart rate, respi[INVESTIGATOR_697], and temperature) after subject has been 
VHDWHGIRU¬ïPLQXWHV  
‚Ä¢ Assess inclusion/exclusion criteria.   
‚Ä¢ Subject to complete the GSP assessment; will be conducted from 7:00 am to 11:00 am . 
‚Ä¢ Subject to complete the HDSM -Ax assessment.  
o Subject to complete  PGI-S administered as Question #6 at the end of the HDSM- Ax questionnaire.  
‚Ä¢ Subject s ¬ï [ADDRESS_740492]. 
o Refer to Appendix 4. 
‚Ä¢ Perform local tolerability assessments (see Section 8.1.5 ).  
‚Ä¢ Review changes to the subject‚Äôs health (AEs).  
‚Ä¢ Perform urine pregnancy t esting (UPT) if applicable (FOCBP only). If positive, the subject shall be 
excluded from the study. 
‚Ä¢ Provided the sub ject has passed all inclusion/exclusion criteria, randomize the subject according to 
separate instruction s.   
‚Ä¢ Pull from inventory the pump container whose unique identifier matches that assigned by [CONTACT_563656] . Record the unique IP gel pump container number on the source document. Dispense 
study product container 1 (of 2) to the subject as follows:  
o Write subject number and initials on the study product container label.  
o Prime the pump (5 actuations) and discard expressed gel.   
o Weigh the primed pump with the applicator cap on and record in source prior to dispensing to the 
subject. Dispense the pump to the subject in the kit carton with the included [ADDRESS_740493] the study drug application procedure (r efer to Appendix 6 ). 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740494] application of study medication at home the evening of Visit 4  
(Baseline visit) . 
‚Ä¢ Review concomitant medications/treatments.  
‚Ä¢ Schedule the subject to return for the next study visit.  
7.2.4  Visit  5: Day 8 ¬± 2 Days 
The following activities will be conducted:  
‚Ä¢ Collect vital signs (blood pressure, heart rate, respi[INVESTIGATOR_697], and temperature) after subject has been 
seated for ‚â•2 minutes ( see Section 8.1.2 ). 
‚Ä¢ Subject to complete the GSP assessment; will be conducted from 7:00 am to 11:00 am.  
‚Ä¢ Subject to complete HDSM -Ax a ssessment .   
o Subject to complete PGI -S administered as Question #6 at the en d of the HDSM- Ax questionnaire.  
‚Ä¢ Perform loca l tolerability assessments .  
‚Ä¢ Review changes to the subject‚Äôs health ( AEs). 
‚Ä¢ Evaluate subject compliance:  
o Ask subjects whether they applied the study product to the right and left axilla each evening as 
directed a nd confirm reason for any missed doses.  
o Verbally confirm application process.   
‚Ä¢ Review concomitant medications/treatments.  
‚Ä¢ Schedule the subject to return for the next study visit.   
7.2.5  Visit  6: Day 15 ¬± 2 Days  
The following activities will be conducted:  
‚Ä¢ Collect vital signs (blood pressure, heart rate, respi[INVESTIGATOR_697] , and temperature) after subject has been 
seated for ‚â•2 minutes.  
‚Ä¢ Subject to complete the GSP assessment; will be conducted from 7:00 am to 11:00 am . 
‚Ä¢ Subject to complete HDSM -Ax assessment.  
o Subject to complete PGI -S administered as Question #6 at the end of the HDSM- Ax questionnaire.  
‚Ä¢ Subject to complete the DLQI  questionnaire. 
‚Ä¢ Perform local tolerab ility assessments .  
‚Ä¢ Review changes to the subject‚Äôs health ( AEs). 
‚Ä¢ Evaluate subject compliance:  
o Ask subjects whether they applied the study product to the right and left axilla each evening as 
directed and confirm reason for any missed doses.  
o Verbally confirm application process.   
‚Ä¢ Review concomitant medications/treatments.  
‚Ä¢ Remind subject to bring their study medication to next visit.  
‚Ä¢ Schedule the subject to return for the next study visit.   
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 34 of 102 
CONFIDE NTIAL                06 AUG 2020  
7.2.6  Visit 7: Day 22 ¬± 2 Days  
The following activities will be conducted:  
‚Ä¢ Collect vital signs (blood pressure, heart rate, respi[INVESTIGATOR_7137] e, and temperature) after subject has been 
seated for ‚â•2 minutes.  
‚Ä¢ Subject to complete the GSP assessment; will be conducted from 7:00 am to 11:00 am . 
‚Ä¢ Subject to complete HDSM -Ax assessment .  
o Subject to complete PGI -S administered as Question #6 at the end  of the HDSM -Ax questionnaire.  
‚Ä¢ Perform local tolerab ility assessments .  
‚Ä¢ Review changes to the subject‚Äôs health ( AEs). 
‚Ä¢ Evaluate subject compliance:  
o Ask subjects whether they applied the study product to the right and left axilla each evening as 
directed and confirm reason for any missed doses.  
o Verbally confirm application process.   
‚Ä¢ Collect subject‚Äôs previously dispensed study product container, weigh with the applicator  cap on, and 
record weight of container.  
‚Ä¢ Dispense study product container (2 of 2 ). 
o Access the IRT system to obtain the number of the next assigned pump container to dispense. Pull 
from inventory the pump container whose unique identifier matches that assigned by [CONTACT_155111]. Record the unique IP gel pump container number on the source document.  
o Write subject number and initials on the study product container label.  
o Prime the pump (5 actuations) and discard expressed gel.   
o Weigh the primed pump with t he applicator cap on and record in source prior to dispensing to the 
subject.  
‚Ä¢ Review concomitant medications/treatments.  
‚Ä¢ Schedule the subject to return for the next study visit.   
7.2.7  Visit 8: Day 29 ¬± 2 Days  
The following activities will be conducted:  
‚Ä¢ Collect vital signs (blood pressure, heart rate, respi[INVESTIGATOR_697] , and temperature) after subject has been 
seated for ‚â•2 minutes.  
‚Ä¢ Subject to complete the GSP assessmen t; will be conducted from 7:00 am to 11:00 am . 
‚Ä¢ Subject to complete HDSM -Ax assessment.  
o Subject to complete PGI -S administered as Question #6 at the end of the HDSM- Ax questionnaire.  
‚Ä¢ Perform local tolerability assessments.  
‚Ä¢ Review changes to the subject‚Äôs health (AEs).  
‚Ä¢ Evaluate subject compliance:  
o Ask subjects whether they applied the study product to the right and left axilla each evening as 
directed and confirm reason for any missed doses.  
o Verbally confirm application process.   
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 35 of 102 
CONFIDE NTIAL                06 AUG 2020  
‚Ä¢ Perform UPT if applicable (FOCBP only). If positive, the subject shall be withdrawn from the study.   
‚Ä¢ Review con comitant medications/treatments.  
‚Ä¢ Schedule the subject to return for the next study visit.   
7.2.8  Visit  9: Day 36 ¬± 2 Days  
The following activities will be conducted:  
‚Ä¢ Collect vital signs (blood pressure, heart rate, respi[INVESTIGATOR_7146]) after subje ct has been 
seated for ‚â•2 minutes.  
‚Ä¢ Subject to complete the GSP assessment; will be conducted from 7:00 am to 11:00 am . 
‚Ä¢ Subject to complete HDSM -Ax assessment.  
o Subject to complete PGI -S administered as Question #6 at the end of the HDSM- Ax questionnaire.  
‚Ä¢ Perform local tolerability assessments.  
‚Ä¢ Review changes to the subject‚Äôs health (AEs).  
‚Ä¢ Evaluate subject compliance:  
o Ask subjects whether they applied the study product to the right and left axilla each evening as 
directed and confirm reason for any missed  doses.  
o Verbally confirm application process.   
‚Ä¢ Review concomitant medications/treatments.  
‚Ä¢ Schedule the subject to return for the next study visit.   
7.2.9  Visits 10 and 11 : GSP4  (Day 41)  ¬± 2 Days  and GSP 5  (Day 42 ) ¬± 2 Days  
Visits 10  and 11 will occur as separate visits  on Days 41 and 42.      
The following activities will be conducted:  
‚Ä¢ Subject t o complete the GSP assessment; will be conducted from 7:00 am to 11:00 am . 
‚Ä¢ Subject to complete HDSM -Ax assessment.  
o Subject to complete PGI -S admini stered as Question #6  at the end of the HDSM- Ax questionnaire.  
‚Ä¢ Review changes to the subject‚Äôs health (AEs).  
‚Ä¢ Evaluate subject compliance:  
o Ask subjects whether they applied the study product to the right and left axilla each evening as 
directed and confirm reason for any missed doses.  
o Verbally confirm application process.   
‚Ä¢ Review concomitant medications/treatments.  
‚Ä¢ At Visit 11, r emind subject to bring their study medication to next visit.  
‚Ä¢ Schedule the subject to return for the next study visit.   
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 36 of 102 
CONFIDE NTIAL                06 AUG 2020  
7.2.10  Visit 12: GSP6 ( Day 43 ; End of Treatment ) ¬± 2 Days  
The following activities will be conducted:  
‚Ä¢ Collect vital signs (blood pressure, heart rate, respi[INVESTIGATOR_7146]) after subject has been 
seated for ‚â•2 minutes.  
‚Ä¢ Subject to complete the GSP assessme nt; will be conducted from 7:00 am to 11:00 am . 
‚Ä¢ Subject to complete HDSM -Ax assessment.  
o Subject to complete PGI -S administered as Question #[ADDRESS_740495] to complete PGI -C administered as Question # 7 at the end of the HDSM -Ax 
questionnaire. 
‚Ä¢ Subject to complete the DLQI questionnaire. 
‚Ä¢ Perform local tolerability assessments.  
‚Ä¢ Review changes to the subject‚Äôs health (AEs).  
‚Ä¢ Collect subject‚Äôs previously dispensed study product container, weigh with the applicator  cap on, and 
record weight of container.  
‚Ä¢ Evaluate subject compliance:  
o Ask subjects whether they applied the study product to the right and left axilla each evening as 
directed and confirm reason for any missed doses.  
o Verbally confirm application process.   
‚Ä¢ Collect samples for laboratory assessments (hematology, chemistry , and urinalysis).   
‚Ä¢ Perform UPT if applicable (FOCBP only). If positive, the subject shall be withdrawn from the study.   
‚Ä¢ Review concomitant medications/treatments.  
‚Ä¢ Schedule the subject to return for the next study visit.   
7.2.11  Visit 13: Follow -up (Day 57 ) ¬± 3 Days  
The following activities will be conducted:  
‚Ä¢ Collect vital signs (blood pressure, heart rate, respi[INVESTIGATOR_7146]) after subject has been 
seated for ‚â•2 minutes.  
‚Ä¢ Subject to complete the GSP assessment; will be conducted from 7:00 am to 11:00 am . 
‚Ä¢ Subject to complete HDSM -Ax assessment.  
o Subject to complete PGI -S administered as Question #6 at the end of the HDSM- Ax questionnaire.  
‚Ä¢ Subject V¬ï\HDUVRIDJH  to complete optional End of Study Survey. 
‚Ä¢ Perform local tolerability assessments.  
‚Ä¢ Review changes to the subject‚Äôs health ( AEs). 
‚Ä¢ Review concomitant medications/treatments.  
‚Ä¢ Discharge subject from the study. 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740496]‚Äôs participation if the subject ‚Äôs health or 
wellbeing is threatened by [CONTACT_118862]. In the event of premature discontinuation, the Investigator 
should determine the primary reason for discontinuation. A subject may be discontinued from the study if any of 
the following circumstances occur:  
‚Ä¢ The subject experiences a SAE  rendering him or her unable to continue study participation. 
‚Ä¢ The subject experiences an AE that in  the opi[INVESTIGATOR_2511] I nvestigator may pose a significant risk for continued 
participation of the subject in the study . 
‚Ä¢ The subject is unable to physically or mentally tolerate the use of the investigational product . 
‚Ä¢ An exclusion criterion becomes apparent a t any time during the study ; the Medical Monitor must be contact[CONTACT_563657].  
‚Ä¢ The subject is not compliant with the study procedures ; the Medical Monitor must be contact[CONTACT_563658].  
‚Ä¢ The subject voluntarily withdraws  from the study. When possible, attempt to identify  the reason the subject 
withdrew consent and document with particular attention paid to whether an underlying AE is at cause.  
‚Ä¢ The subject becomes pregn ant. 
‚Ä¢ If for any reason per the Investigator‚Äôs or the Sponsor‚Äôs judgment, discontinuation is in the subject‚Äôs best 
interest.  
Subjects who discontinue the study prior to the completion of all treatment visits will be asked to complete the 
evalu ations corresponding to Visit 12 (Day 43, End of Treatment). The Sponsor will be notified of early 
discontinuation as soon as possible during the study.  
8 RESPO NSE MEASURES A ND SUMMARY OF DATA CO LLECTIO N METHODS  
8.1 Safety Measures  
The following safety assessment measures will be conducted as indicated in  Section 7.1, Time and Events Table.  
‚Ä¢ Physical exam ination  
‚Ä¢ Vital signs (blood pressure, pulse rate, respi[INVESTIGATOR_697], and temperature)  
‚Ä¢ Laboratory te sts (hematology, chemistry , urinalysis ) and pregnancy testing in FOCBP 
‚Ä¢ Collection of AEs 
‚Ä¢ Local tolerability assessments  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 38 of 102 
CONFIDE NTIAL                06 AUG 2020  
8.1.1  Physical Exam ination  
Physical examination will include assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, 
lungs, cardiovascular, abdomen (liver and spleen), lymph nodes,  and extremities. Height and weight will also be 
measured and recorded.  
8.1.2  Vital Signs  
Subjects should be seated for ‚â•2 minutes prior to measurements. Pulse rate (bpm) will be counted over 
60 seconds. Blood pressure (mmHg) will be measured with a sphygmomanometer. 
Vital sign measurements will include systolic and diastolic blood pressure, pulse rate , respi[INVESTIGATOR_697],  and 
temperature.  
8.1.3  Clinical Laboratory Assessments  
Hematology, clinical chemistry, urinalysis , and additional parameters to be tested are listed below:  Hematology Platelet count  RBC Indices : Automated WBC Differential : 
Red blood cell ( RBC ) count Mean corpuscular volume ( MCV ) Neutrophils  
White blood cell ( WBC ) count  Mean corpuscular hemoglobin ( MCH ) Lymphocytes  
Reticulocyte count Mean corpuscular hemoglobin concentration 
(MCHC ) Monocytes  
Hemoglobin   Eosinophils  
Hematocrit   Basophils  
 
Clinical Chemistry  
Blood urea nitrogen  Chloride  Alkaline phosphatase  
Creatinine  Aspartate aminotransferase (AST ) Total and direct bilirubin  
Sodium  Alanine aminotransferase ( ALT)  
Potassium  Gamma glutamyl transferase ( GGT )  
 Routine Urinalysis Bilirubin, color, appearance, glucose, ketones, leukocyte esterase, nitrite, occult blood, pH, protein, specific gravity , and 
urobilinogen  
Microscopic examination (if blood or protein is abnormal)  
 Other Screening Tests Urine Pregnancy Test (females of childbearing potential* only, using UPT tests provided by  [CONTACT_1034].)  
* Females  of childbearing potential for this study includes any female capable of becoming pregnant who has not undergone 
successful surgical sterilization (hysterectomy, bilateral tubal ligation [‚â•6 months prior to baseline ], or bilateral 
oophorectomy) or is not postmenopausal (defined as amenorrhea ¬ï12 consecutive months).  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740497]‚Äôs documentation.  
8.1.4  Adverse Events  
Adverse events ( AEs; see Section  9.2) will be collected for all untoward medical occurrences in a subject entered 
into this clinical study (e.g., signed consent), w hether or not a pharmaceutical product has been administered. 
Any event, including local tolerability assessments (see Section  8.1.5 ), that requires specific treatment, results in 
interruption of treatment, or results in discontinuation of the subject from the study will also be reported as an 
AE.   
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and non-leading verbal 
questioning of the subject is the preferred method to inquire about AE occurrence.   
Appropriate questions include:  
‚Ä¢ ‚ÄúHow are you feeling?‚Äù  
‚Ä¢ ‚ÄúHave you had any (other) medical problems since your last visit/contact?‚Äù 
‚Ä¢ ‚ÄúHave you taken any new medicines, other than those provided in this study, since your last visit/contact?‚Äù 
8.1.5  Local Tolerability Assessments  
Local tolerabi lity assessments ( see Appendix 5 ) will be evaluated through assessment of symptoms at the drug  
application site. These assessments are to be performed for both axillae individually. Subject assessments will be 
made prior to the Investigator assessments.  
Subject Local Tolerability Assessments:  Subjects will be queried about whether any symptoms occurred at the 
study drug application site within the previous 24 hours and further whether any such symptoms persisted longer 
than 1 hour following study drug ap plication. Standardized scales will be used to describe specifically the 
severity of any burning, stinging, or itching.  
Investigator Local Tolerability Assessments: Investigators will observe for the existence of any significant 
local symptoms at the  study drug application site. Significant local symptoms are defined as those not ordinarily 
observed following application of a topi[INVESTIGATOR_119029]. Standardized scales will be used to describe specifically the 
severity of any erythema or scaling. 
Local tolerability signs and symptoms that result in a subject requiring a concomitant therapy, interruption of 
treatment, or discontinuation from the study, will be reported as AEs.  
8.1.[ADDRESS_740498] complete ALL self -assessments while at  the clinic (i.e., HDSM -Ax, DLQI, PGI- S, PGI-C ) prior to 
assessments being made by [CONTACT_737]. Please see Appendix 2  and Appendix 3  (HDSM -Ax by [CONTACT_654] ; also 
includes PGI- S and PGI -C) and Appendix 4  (DLQI)  for a full description of these assessments.  Subjects will also 
have the option to complete an End of Study Survey. The HDSM -Ax, DLQI, P GI-S, and PGI- C assessments, as 
well as the optional End of Study Survey, will be collected electronically using a table t device. Site personnel 
will be trained and a separate electronic clinical outcomes assessment (eCOA ) manual will be supplied. 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740499] Dermatitis (Skin Sensitization) Assessment  
Allergic contact [CONTACT_8748] (ACD), as an AE, may manifest as moderate/severe pruritis and moderate/severe 
erythem a with or without vesicles/bullae.  
In the case of a suspected AE of ACD, the medical monitor should be contact[CONTACT_224817]. If the 
medical monitor and the investigator agree that the AE is suggestive of ACD, the assigned treatment should be 
withh eld, the AE documented, and treated, if required, by [CONTACT_563659][INVESTIGATOR_563623]. Once the AE of ACD is resolved, in the opi[INVESTIGATOR_1070], any concomitant therapy for this AE should be stopped, and the assigned treatment should be 
restarted (i.e., re -challenge exposure) after discussion with the medical monitor. If there is recurrence, an AE of 
ACD  is confirmed and should be documented as an AE that is related to the assigned treatment.  
8.2 Summary of Methods of Data Collection  
This protocol will utilize validated 21 Code of Federal Regulations ( CFR ) Part 11 complia nt electronic data 
capture ( EDC ) software  and eCOA software  to collect required study data. The Investigator must ensure that data 
are properly recorded on each subject‚Äôs eCRFs , eCOAs , and related documents. When changes or corrections are 
made in the eCRF, the EDC  system s will maintain an audit trail of the person making the changes, the date and 
time of the change, and the reason for the change. Only individuals listed on the Delegation of Responsibilities 
Log with responsibility for eCRF completion may make entries in the eCRFs. 
The Investigator or physician Sub-I nvestigator must electronically sign and date each subject‚Äôs eCRF  for each 
timepoint completed. Individuals who will be providing electronic signatures must first submit documentation 
with a handwritten signature [CONTACT_28285] a legally binding equivalent to their 
handwritt en signature.  
8.3 Efficacy Measures  
The following assessment measures will be conducted to evaluate the long-term efficacy of  sofpi[INVESTIGATOR_519673], 15% as indicated in the Procedures  Section 7.1: 
‚Ä¢ HDSM -Ax as measured by [CONTACT_423]  
‚Ä¢ GSP as measured by [CONTACT_737] 
‚Ä¢ DLQI as measured by [CONTACT_423]  (for subjects ¬ï17 years of age)  
‚Ä¢ Patient Global Impression Scales ; Severity ( PGI-S) and Change ( PGI-C)  
9 ADVERSE EVE NTS (AE) AND SERIOUS ADVERSE EVE NTS (SAE)  
9.[ADDRESS_740500] entered this study and report 
all SAEs to the  CRO  (see Section  9.3.1 ). Contact [CONTACT_31036]‚Äôs M edical Monitor is provided on 
the protocol cover page.  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 41 of 102 
CONFIDE NTIAL                06 AUG 2020  
9.2 Adverse Events  
9.2.1  Definitions of Adverse Events  
According to 21 CFR Parts 312.32 and 320.32 (IND Safety Reporting, Applicability of R equirements Regarding 
an "Invest igational New Drug Application" ), Food and Drug Administration ( FDA ) Guidance for Industry 
(Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety 
Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans) (Federal Register/Vol. 75, 
No. 188/September 29, 2010) and International Council on Harmonisation ( ICH) E2A (Clinical Safety and Data 
Management: Definitions and Sta ndards for Expedited Reporting): 
An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. 
A suspected adverse reaction (SAR) means any AE for which there is a reasonable possibility that the drug 
caused the AE. 
The following information should be considered when determining whether or not to classify a test result, 
medical condition, or other incident as an AE: 
Adverse events will be recorded from the time of in formed consent. 
Abnormal laboratory values should not generally be recorded as AEs unless an intervention is required, the 
laboratory abnormality results in a n SAE , the lab abnormality results in study termination or 
interruption/discontinuation of study t reatment, or the lab abnormality is associated with clinical signs or 
symptoms. When recording an AE resulting from a laboratory abnormality, the resulting medical condition rather 
than the abnormality itself should be recorded (e.g., record ‚Äúanemia‚Äù rather than ‚Äúlow hemoglobin‚Äù). 
Complications that occur in association with a protocol-mandated intervention (e.g., invasive procedures such as 
biopsies) should be recorded as AEs. 
Whenever possible, the Investigator should group signs or symptoms that constitute a single diagnosis under a 
single event term. For example, cough, rhinitis, and sneezing might be grouped together as ‚Äúupper respi[INVESTIGATOR_19629] .‚Äù If possible, abnormal laboratory results that meet the definition of an AE (see above) should be 
reported as a clinical diagnosis rather than the abnormal value itself (e.g., ‚Äúanemia‚Äù rather than ‚Äúdecreased blood 
count‚Äù). 
[IP_ADDRESS]  Documentation and Monitoring Adverse Events  
All AEs encountered during the clinical trial following subject consent through the last study drug visit will be 
recorded on the appropriate Adverse Events e CRF.  
Special considerations:  
Elective procedures or routinely scheduled treatments are not considered AEs. However, an untoward medical 
event occurring in association with a preschedule d elective procedure should be recorded as an AE. 
A baseline condition is not considered an AE unless the condition worsens following study drug administration. 
Death itself is not considered an AE; it is, instead, the outcome of an AE. 
SAEs  that are considered related (i.e., determined to be possibly, probably, or definitely related) to sofpi[INVESTIGATOR_563624] (see Section 9.4). 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 42 of 102 
CONFIDE NTIAL                06 AUG 2020  
[IP_ADDRESS]  Assessment of Adverse Events  
For each AE, the start and resolution  dates, intensity, seriousness ( i.e., whether the event meets the definition of 
an SAE [Section 9.3.1 ]), relationship of the event to the study drug, action taken regarding study drug, and 
outcome of the event will be documented on the e CRF.  
Intensity  
The following definitions should be used to assess and grade AE intensity, including laboratory abnormalities 
judged to be clinically significant.  
Severity  Grade  Description  
Mild  1 Awareness of sign or symptom, but easily tolerated  
Moderate  2 Discomfort enough to cause interference with usual activity  
Severe  3 Incapacitating with inability to work or do usual activity  
Note: a severe adverse event is not necessarily serious.  
Relationship  
The relationship of an AE to study drug should be assessed using the guidelines presented in the table below. An 
AE for which there has been no causal relationship reported will require follow-up to determine causality. 
Adverse Event Relationships to Study Drug  
Degree of Certainty  Description  
Definitely Related  An event that follows a reasonable temporal sequence from administration of the test article; 
that follows a known or expected response pattern to the test article; and that is confirmed by 
[CONTACT_3895][INVESTIGATOR_47732], and reappearance of the event on repeated 
exposure (re -challenge).  
Probably Related  An event that follows a reasonable temporal sequence from administration of the test article; 
that follows a known or expected response pattern to the  test article; and that is confirmed by 
[CONTACT_3895][INVESTIGATOR_229767]; and that is unlikely to have 
been caused by [CONTACT_28260]/underlying illness or other drugs, procedures, or other causes.  
Possibly Related  An event th at follows a reasonable temporal sequence from administration of the test article; 
that follows a known or expected response pattern to the test article; but may have been caused 
by [CONTACT_28260]/underlying illness, other drug, procedure, or other causes.  
Unlikely Related  An event that does not follow a reasonable temporal sequence from administration of the test 
article; that does not follow a known or expected response pattern to the test article, or most 
likely was caused by [CONTACT_28260]/underlying illness , other drug, procedure, or other causes, 
because of their known effects.  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740501] certainly caused by [CONTACT_28260]/underlying illness, other drug, procedure, or 
other causes.  
 
Outcome  
Each AE will be characterized according to the outcomes described in the following table:  
Outcome  Description  
Recovered/Resolved  The subject has fully recovered from the event with no observable 
residual effects.  
Recovering/Resolving  The effects of the event are improving, or events have stabilized (are 
constant and not expected to improve or worsen) but have not returned 
to baseline.  
Not recovered/ Not Resolved  The effects of the event are still present and changing. The event is not 
considered stabilized or resolved.  
Recovered/Resolved with Sequelae  The subject has fully recovered from the event with some observable 
residual effects.  
Fatal  The event was the primary cause of death (may or may not be the 
immediate cause of death).  
Unknown  The event outcome is unknown.  
Death is an outcome of an event and not an event per se . Sudden death or death due to unexplainable cause(s) is 
to be reported, but follow-up will be pursued until cause of death is determined. 
Action Taken with Study Drug  
Action taken with study drug in relation to each adverse event will be characterized as follows:  
‚Ä¢ None 
‚Ä¢ Drug withdrawn  
‚Ä¢ Drug interrupted  
‚Ä¢ Dose reduction 
‚Ä¢ Unknown 
‚Ä¢ Not applicable 
‚Ä¢ Other (specify on e CRF)  
9.3 Serious Adverse Events  
Any AE that is serious (see definition below) and occurs after administration of study drug must be reported to 
the CRO  Medical Monitor  within [ADDRESS_740502] also be reported to the CRO within 24 hours of discovery of the event. 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 44 of 102 
CONFIDE NTIAL                06 AUG 2020  
9.3.1  Definition and Reporting Procedures  
An AE  should be classified as an SAE  if it meets one of the following cri teria:  
Fatal:  The adverse event resulted in death.  
Life Threatening:  The adverse event placed the subject  at immediate risk of death. This classification does not 
apply to an adverse event that hypothetically might cause death if it were more severe.  
Hospi[INVESTIGATOR_059]:  The adverse event required or prolonged an existing inpatient hospi[INVESTIGATOR_059]. Hospi[INVESTIGATOR_563625] -ups are not serious adverse events by [CONTACT_46668].  Hospi[INVESTIGATOR_563626].  
Disabling/Incapacitating:  Resulted in a substantial and permanent disruption of the subject ‚Äôs ability to carry  out 
activities of daily living.  
Congenital Anomaly or Birth 
Defect:  An adverse outcome in a child or fetus of a subject  exposed to the study drug or study 
treatment regimen before conception or during pregnancy.  
Medically Significant:  The adverse event did not meet any of the above criteria, but could have jeopardized the 
subject  and might have required medical or surgical intervention to prevent one of the 
outcomes listed above.  
Every SAE (regardless of suspected causality) should be reported to the CRO  Medical Monitor  within [ADDRESS_740503] /Institutional Ethics 
Committee  (IRB/IEC ) in accordance with federal and institutional laws and regulations.  
Additional updates from the I nvestigator may be necessary as more information becomes availab le on the SAE, 
and all treatment -related SAEs will be followed until the acute event has resolved or stabilized, even if the 
subject discontinues study participation prior to the SAE resolution. Any new information or follow-up 
information pertaining to previously reported SAEs will be reported to the CRO  Medical Monitor  within 24 
hours of becoming aware of the new or follow-up information. The new or follow-up information should be 
faxed to [PHONE_221] (US toll- free: 1 -[PHONE_222]) or e- mailed to safety -[EMAIL_207].  
Any SAE that occurs after study completion, and is considered by [CONTACT_941] I nvestigator to be related to sofpi[INVESTIGATOR_563627], should be reported to the Sponsor. 
Reporting Serious Adverse Events to Regulatory Agencies  
The Sponsor will determine which SAEs qualify for expedited reporting to regulatory agencies. SAEs that 
qualify for expedited reporting will be submitted to regulatory agencies in accordance with federal regulation 
(21 CFR 312.32).  
9.[ADDRESS_740504] signs informed consent 
through the final study visit.  SAEs  that are considered related to study drug by [CONTACT_563660] d until the events resolve or stabilize.  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 45 of 102 
CONFIDE NTIAL                06 AUG 2020  
9.5 Pregnancy Reporting  
Sexually active females of childbearing potential (FOCBP) * must have a negative pregnancy test prior to study 
enrollment and must use an acceptable  method of contraception during the course of the study, in a manner such 
that risk of failure is minimized. Prior to study enrollment, FOCBP must be advised of the importance of 
avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy. The 
subject must sign an informed consent form documenting this discussion. 
FOCBP must agree to periodic pregnancy testing and use a medically acceptable method of contraception for the 
duration of the study. This includes perimenopausal women who are <[ADDRESS_740505] menses. 
Acceptable contraceptive methods include the following:  
‚Ä¢ Abstinence for the duration of the study or where partner is sterile (e.g., vasectomy); OR 
‚Ä¢ Hormonal contraception, including oral, injectable, or implantable methods started ‚â•2 months  prior to 
screening; OR  
‚Ä¢ Non-hormonal contrace ption, including IUD ( ‚â•1-week status post placement) or properly used barrier 
methods (e.g., male or female condoms with or without spermicide, cervical cap/diaphragm  with 
spermicid e). 
* FOCBP for this study includes any premenopausal female capable of becoming pregnant who has not 
undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation [ ‚â•6 months prior to baseline] or 
bilateral oophorectomy) or is not postmeno pausal (defined as amenorrhea ‚â•12 consecutive months ).   
Subjects who become sexually active or begin to have relations with a partner who is not sterile during the trial 
must agree to use an ac ceptable form of birth control for the duration of the study. 
9.5.[ADDRESS_740506] they might be pregnant (e.g., 
missed or late menstrual period). If a subject or Investigator suspects that a subject may be  pregnant at any time 
during the study, the investigational product must be withheld until the results of laboratory pregnancy testing are 
available. If pregnancy is confirmed, the subject must not receive or apply further investigational product and 
must be discontinued from the study. 
9.5.[ADDRESS_740507] the pregnancy on the appropriate pregnancy surveillance 
form. The form will be sent to the CRO  Medical Monitor by [CONTACT_12100] [PHONE_221] (US toll- free: [PHONE_2626]) 
or e-mailed to safety -[EMAIL_207]. The Investigator must notify the IRB of any pregnancy 
associated with the study therapy and keep careful source documentation of the event.  
Protocol- required procedures for those subjects that are discontinued from the study must be performed on the 
subject unless contraindicated by [CONTACT_8663] (e.g., x-ray studies). Other appropriate pregnancy follow-up 
procedures should be considered if indicated, including counseling of the subject by [CONTACT_563661] (e.g., obstetrician). In addition, the I nvestigator must report to the 
CRO Medical Monitor, on the appropriate pregnancy surveillance form(s), any follow- up information regarding 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 46 of 102 
CONFIDE NTIAL                06 AUG 2020  
the course of the pregnancy, including perinatal (period immediately before and after birth) and neonatal (infants 
up to 28 days after birth) outcome.   
Although pregnancy itself is not an AE, any complications during pregnancy should be recorded as AEs (or 
SAEs , if they fu lfill the SAE criteria). Offspring will be followed for a minimum of eight weeks.  Any 
congenital anomaly/birth defect in a child born to a subject exposed to the test article(s) will be recorded as a 
SAE and details documented in the pregnancy surveillance form. An abortion, whether accidental, therapeutic, 
elective or spontaneous, will be reported as a SAE.  
9.6 Other Safety Measures  
Safety will also be assessed by [CONTACT_31029] , laboratory tests, and measurement of vital signs assessed 
as indicated thr oughout the study schedule. Clinically significant changes in these parameters may be captured as 
adverse events.  
10 STATISTICAL PROCEDUR ES 
A detailed statistical analysis plan  (SAP)  will be generated prior to the final database lock . Database lock will 
follow completion of data entry, verification and validation, database audit, and data clarification resolution. 
10.1 Analysis Populations  
The t hree analysis populations for this study are defined below. Identification of the subjects to be included in 
each analysis population will be determined and finalized prior to database unmasking.  
10.1.1  Intent -to-Treat Population  
The Intent -to-Treat ( ITT) Population will include all subjects who were randomized. Subjects will be analyzed 
according to the treatment group to which they were randomized, regardless of post-randomization protocol 
deviations, including no treatment or wrong treatment received. 
10.1.2  Per-Protocol Population  
The PP  Population will be a subset of the ITT Population and will include subjects who meet the following 
criteria:  
‚Ä¢ Meets all inclusion/exclusion criteria  
‚Ä¢ Has not taken or applied any interfering concomitant medications 
‚Ä¢ Completed the following visits:  
o Visit 2 GSP 1, and the required GSP data collection  
o Visit 3 GSP 2, and the required GSP data collection  
o Visit 4 (Day 1) Re-screening /Baseline  GSP 3  and HDSM -Ax, and the required GSP and HDSM -Ax 
data collection  
o Visit 10 (GSP 4) Day 41 (¬± 2 days), and the required GSP data collection  
o Visit 11  (GSP 5) Day 42 (¬± 2 days), and the required GSP data collection  
o Visit 1 2 (GSP 6) Day 43 (¬± 2 days) and HDSM -Ax, and the required GSP and HDSM -Ax data 
collection  
 
Sofpi[INVESTIGATOR_563575]-4000- CL-302/03 Page 47 of 102 
CONFIDE NTIAL       06 AUG 2020  
10.1.3  Safety Population 
The Safety Population will include all subjects randomized in the study who received study drug, either vehicle 
or sofpi[INVESTIGATOR_519654], 15%, at least once.  If a subject receive d any sofpi[INVESTIGATOR_519654], 15%, the 
subject will be analyzed  in the sofpi[INVESTIGATOR_519654], 15%, treatment group . Otherwise the subject will be 
included in the vehicle group. 
10.2 Efficacy Endpoints  
10.2.1  Definitions  
For the purposes of analysis, Baseline and End of Treatment (EOT) definitions for the two primary efficacy 
assessment  measure s, HDSM -Ax-7 and Gravimetric Sweat Production (GSP), are defined below. 
HDSM -Ax  
‚Ä¢Baseline  = Visit 4 (Day 1) assessment
‚Ä¢EOT  = Visit 12 (Day 43) assessment
GSP  
‚Ä¢Baseline  = the median  of GSP1, GSP2, and GSP3 measurements obtained on Visit 2, Visit 3, and Visit 4,
respectively
‚Ä¢EOT  = the median  of GSP4, GSP5, and GSP6 measurements obtained on Visit 10, Visit 11, and Visit 12,
respectively
Note that a t each timepoint, GSP will be defined as the sum of both axillae measurements . If [ADDRESS_740508] for one of the three 
timepoints. 
10.2.2  Co-Primary Efficacy Endpoints  
The following co- primary efficacy endpoints will be analyzed to assess the efficacy of sofpi[INVESTIGATOR_519654], 
15%: 
‚Ä¢The proportion of subjects achieving at least a 2-point improvement in the HDSM- Ax-7 scale score from
baseline to EOT.
‚Ä¢The change in GSP from baseline to EOT.
Note that  the assessment  of the first  co-primar y efficacy endpoint will be conducted using [ADDRESS_740509]  5 items in  section 2 
(7 sub- items  in total) will be used. The mean will be derived by [CONTACT_563662] 7 item s cores  and dividi ng it by 
7.For each of the HDSM-Ax sub-i tems,  missing  values at  EOT  will be imputed  as described  briefly  in
Section  10.3.1 . HDS M-Ax-7 at EOT will be derived from the imputed values. Further details on imputation 
methods will be provided in the SAP.
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 48 of 102 
CONFIDE NTIAL                06 AUG 2020  
10.2.3  Secondary Efficacy Endpoints  
The following secondary efficacy endpoints will be analyzed: 
‚Ä¢ The proportion of subjects achieving at least a 1-point improvement in the HDSM- Ax-7 scale score from 
baseline to EOT.  
‚Ä¢ The proportion of subjects achieving at least a 2-point improvement in the HDSM- Ax-[ADDRESS_740510] a 70% reduction in GSP from baseline to EOT. 
‚Ä¢ The proportion of subjects achieving at least a 1-point improvement in the HDSM- Ax-[ADDRESS_740511] a 50% reduction in GSP from baseline to EOT. 
10.2.4  Exploratory Efficacy Endpoints   
Exploratory  efficacy endpoints to be analyzed include the following: 
‚Ä¢ The proportion of subjects achieving at least a 1-point improvement in the HDSM- Ax-7 scale score from 
baseline to Days 8, 15, 22, 29, 36, 41, 42, 43 (EOT), and 57. 
‚Ä¢ The proportion of subjects achieving at least a 1-point improvement in the HDSM- Ax 11 -Item 
(HDSM -Ax-11) scale score from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43 (EOT), and 57. 
‚Ä¢ The proportion of subjects achiev ing at least a 2 -point improvement in the HDSM- Ax-7 scale score from 
baseline to Days 8, 15, 22, 29, 36, 41, 42, 43 (EOT), and 57. 
‚Ä¢ The proportion of subjects achieving at least a 2-point improvement in the HDSM- Ax-11 scale score from 
baseline to Days 8, 15, 22, 29, 36, 41, 42, 43 (EOT), and 57. 
‚Ä¢ The proportion of subjects achieving at least a 1-point improvement in the HDSM- Ax Question 4 score 
from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43 (EOT), and 57. 
‚Ä¢ The proportion of subjects achieving at least a 2-point improvement in the HDSM- Ax Question 4 score 
from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43 (EOT), and 57. 
‚Ä¢ The proportion of subjects achieving at least a 1-point improvement in the HDSM- Ax Questi on 5 score 
from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43 (EOT), and 57. 
‚Ä¢ The proportion of subjects achieving at least a 2-point improvement in the HDSM-Ax Question 5 score 
from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43, (EOT), and 57.  
‚Ä¢ Change in PGI-S from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43 (EOT) , and 57.  
‚Ä¢ PGI-C score on Day 43 (EOT) .  
‚Ä¢ The proportion of subjects achieving at least a 2-point improvement in the HDSM- Ax-[ADDRESS_740512] a 70% reduction in GSP from baseline to EOT. 
‚Ä¢ The proportion of subjects achieving at least a 1-point improvement in the HDSM- Ax-[ADDRESS_740513] a 50% reduction in GSP from baseline to EOT. 
‚Ä¢ The proportion of subjec ts achieving at least a [ADDRESS_740514] a 70% reduction  in GSP from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43, EOT , and 
Day 57. 
‚Ä¢ The proportion of subjects achieving at least a 2-point improvement in the HDSM -Ax-[ADDRESS_740515] a 70% reduction in GSP from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43, EOT , and 
Day 57. 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 49 of 102 
CONFIDE NTIAL                06 AUG 2020  
‚Ä¢ The proportion of subjects achieving at least a 1-point improvement in the HDSM- Ax-[ADDRESS_740516] a 50% reduction in GSP from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43, EOT , and 
Day 57. 
‚Ä¢ The proportion of subjects achieving at least a 1-point improvement in the HDSM- Ax-[ADDRESS_740517] a 50% reduction in GSP from bas eline to Days 8, 15, 22, 29, 36, 41, 42, 43, EOT , and 
Day 57. 
‚Ä¢ Change in HDSM- Ax-7 scale score  from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43 (EOT),  and 57 as a 
continuous measure.  
‚Ä¢ Change in HDSM- Ax-11 scale score from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43 (EOT), and 57 as 
a continuous measure.  
‚Ä¢ The proportion of subjects achieving at least a 70% reduction in GSP from baseline to Days 8, 15, 22, 29, 
36, 41, 42, 43, EOT, and Day 57.  
‚Ä¢ The proportion of subjects achieving at least a 50% reduction  in GSP from baseline to Days 8, 15, 22, 29, 
36, 41, 42, 43, EOT, and Day 57. 
‚Ä¢ The rank-based GSP change from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43, EOT, and Day 57. 
‚Ä¢ The absolute GSP change from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43, EOT, and Day 57. 
‚Ä¢ The percent change from baseline in GSP from baseline to Days 8, 15, 22, 29, 36, 41, 42, 43, EOT, and 
Day 57. 
‚Ä¢ The change in the modified DLQI from baseline to Day 15 and Day 43 (EOT). 
10.3 Analysis Methods  
The primary efficacy analysis will be performed on the ITT population with missing values imputed. The co-
primary efficacy endpoints are: 
‚Ä¢ The proportion of subjects achieving at least a 2-point improvement in the HDSM- Ax-7 scale score from 
baseline to EOT  in the sofpi[INVESTIGATOR_519654], 15% group versus vehicle; and 
‚Ä¢ The change in GSP from baseline to EOT in the sofpi[INVESTIGATOR_563628], 15% group versus vehicle . 
Both comparisons will be conducted using two-sided tests at an alpha=0.05 level. Both endpoints will need to 
demonstrate a statistical ly significan t positive result in favor of sofpi[INVESTIGATOR_519654], 15% for the study to be 
considered successful.   
The key elements of the primary efficacy analysis for each co -primary endpoint are described below.  
10.3.1  Primary and Secondary Analysis of the HDSM -Ax-7 Co-Primary Endpoint    
Data:  HDSM -Ax-7  total scores 2-point responder status (0, 1) at EOT . Missing data will be imputed first before 
analysis is performed.  
Imputation Model:  Imputation will be item -level. If a subject is missing values for any of items 1a, 1b, 2a, 2b, 
2c, 2d, or 2e at Visit 4 (Day 1), the Visit 1 (Screening) value will be used as Baseline. If the Visit 1 (Screening) 
value is also missing, the subject will be excluded from all HDSM -Ax-[ADDRESS_740518] (in time) available non-missing value from Day 41 (¬±2 days) or Day 
42 (¬±2 days) will be used as the first level of imputation . Should none of the Days  41, 42, and 43 values be 
available,  multiple imputations  of missing EOT  item-level scores will be performed on the sofpi[INVESTIGATOR_563629]-4000- CL-302/03 Page 50 of 102 
CONFIDE NTIAL                06 AUG 2020  
gel, 15% arm values using a control- based imputations ( CBI) methodology (s ee Section 10.3.4 ). Multiple 
imputations assuming miss ing at random will be performed for missing data for vehicle subjects.  The HDSM -
Ax-7 score will be calculated using the imputed item -level values. Further details on imputation methods will be 
provided in the SAP. 
Analysis Model:   Logistic Regression  Model 
Covariates:   The following covariates  are planned:  
‚Ä¢ Treatment (class effect: sofpi[INVESTIGATOR_519654] , 15% group, vehicle group) 
‚Ä¢ Baseline HDSM -Ax-7 total score  
‚Ä¢ Analysis center  (see Section 10.3.3 ) 
Hypothesis Tested:  
The null hypothesis 
H0: The proportion of subjects achieving at least a 2-point improvement in the HDSM- Ax-7 scale score 
from baseline to EOT  is the same in the sofpi[INVESTIGATOR_519654], 15%, and vehicle arms   
will be tested against the two -sided alternative hypothesis: 
H1: The proportion of subjects achieving at least a 2-point improvement in the HDSM- Ax-7 scale score 
from baseline to EOT  is not the same in the sofpi[INVESTIGATOR_519654], 15%, and vehicle arms . 
Estimand:   The estimand of this co -primary efficacy analysis is the difference  in proportions between 
sofpi[INVESTIGATOR_519654], 15%, and vehicle  arms with a 2 -point improvement from baseline to EOT in 
HDSM -Ax-7 total scores among all ITT subjects, regardless of treatment adherence.  
As a secondary, supportive analysis, change from baseline to EOT will be analyzed as a continuous measure.  
The analysis model will be an ANCOVA model with tr eatment, baseline HDSM -Ax-7 score, and analysis center 
as covariates.  The estimand for this analysis is the difference in mean baseline to EOT changes in HDSM- Ax-7 
total scores between sofpi[INVESTIGATOR_519654], 15%, and vehicle arms among all ITT subjects, regardless of 
treatment adherence.   
In addition, a separate site poolability analysis will be performed with analysis center -by-treatment interaction 
terms added to the primary analysis model. An overall p < 0.[ADDRESS_740519] to account for the potentia l heterogeneity. 
10.3.2  Primary and Secondary Analyse s of the GSP Co -Primary Endpoint    
Data: Either rank -based GSP change from baseline to EOT or continuous GSP change from baseline to EOT will 
be analyzed. The GSP assessment is known to be a highly variable measure , and as such, the Shapi[INVESTIGATOR_563630] -primary endpoint will be continuous or rank transformed. The 
normality test will be performed prior to multiple imputation for missing data and separately for  each arm. 
Should the normality assumption be violated for either arm, the co-primary endpoint will be analyzed using rank-
transformed GSP data. If the normality assumption holds for both arms, then the co-primary endpoint will be 
analyzed using continuous GSP data.  
For the rank transformation  of GSP measurements at a particular time point , continuous data for all subjects will 
be ranked t ogether without regard  to treatment assignment, from smallest to highest value. The smallest 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740520], the continuous GSP data will be 
ranked separately at each of Visits  2, 3, and 4; the median of the three ranks will be used as baseline value of the 
subject.  Using the measurement data from Visits 10, 11, and 12, the rank- transformed GSP value at EOT will be 
derived in the same manner. For each subject, the difference between the rank -transform ed baseline and EOT 
GSP values (EOT ‚Äì baseline) will serve as the outcome value for the rank -based GSP ANCOVA analysis.     
Missing EOT GSP data ( continuous data) will be im puted before analysis is performed.  
Imputation Model:  Imputation will be done using continuous data prior to rank-transformation, should the 
normality assumption be violated. For continuous data, subjects  with results  (see Section 10.3.3 ) meeting the 
criterion for ‚Äúoutlier‚Äù will be removed from imputation sampling database (i.e. , data for v ehicle patients) prior to 
missing data imputation . From the remaining imputation samplin g database  of continuous GSP measurements, 
multiple imputations of missing EOT sofpi[INVESTIGATOR_519666], 15% arm GSP values will be performed using a CBI 
methodology (s ee Section  10.3.4 ). Multiple imputations assuming MAR  will be performed for missing EOT data 
vehicle subjects.  Further details on multiple imputations will be provided in the SAP.  
Analysis Model:  ANCOVA model  (either non-ranked or ranked, pending outcome of normality test)  
Fixed effects:  The following fixed effects are planned: 
‚Ä¢ Treatment (class effect: sofpi[INVESTIGATOR_519654] , 15% group, vehicle group) 
‚Ä¢ Baseline GSP  (either non -ranked or ranked, pending outcome of normality test) 
‚Ä¢ Analysis center  (see Section 10.3.3 ) 
Hypothesis Tested:  
The null hypothesis 
H0: The rank-based  GSP changes from baseline to EOT  are the same in the sofpi[INVESTIGATOR_519654], 
15%, and vehicle groups 
will be tested against the two -sided alternative hypothesis: 
H1: The rank-based  GSP changes from baseline to EOT  are not the same in the sofpi[INVESTIGATOR_519654], 
15%, and vehicle groups. 
Estimand:   The estimand of this co-primary efficacy analysis is the mean  difference  between treatments , 
sofpi[INVESTIGATOR_519654], 15%, versus vehicle , in the change from baseline to EOT for GSP among all ITT 
subjects, regardless of treatment adherence.  
Additionally , the following secondary and supportive analyses will be performed for the GSP co- primary 
endpoint:  
(a) U sing the same methodology as described above,  an ANCOVA analysis will be performed foreither the non-
rank transformed, continuous GSP data, or the rank transformed GSP data, pending the results of the normality 
test. If the normality assumption is violated and the rank -transformed data are used as the co -primary endpoint, 
analysis of the continuous data will be supportive. If the normality assumption holds and the continuous dat a are 
used as the co -primary endpoint, then analysis of the rank-transformed data will be supportive. 
(b) To further address the potential large variations in GSP data, mixed model repeated measures (MMRM) 
analyses will be performed to estimate the  average  sofpi[INVESTIGATOR_519654], 15% treatment effect over the 
6-week course of treatment, i.e. the average sofpi[INVESTIGATOR_519654], 15% v ersus  vehicle difference  from 
Sofpi[INVESTIGATOR_563575]-4000- CL-302/[ADDRESS_740521] to missing data, missing data will not be imputed for this analysis.   In 
addition, based on the BBI-4000 CL- 203 results, treatment versus visit interactions are not expected.  Details of 
the analysis models wi ll be provided in the SAP.   
(c) For the primary endpoint of either ranked or continuous GSP (pending normality test results), a  separate site
poolability analysis will be performed with analysis center -by-treatment interaction terms added to the primary
analysis model. An overall p < 0.[ADDRESS_740522] to account for the potential heterogeneity.
10.3.3  Method of Pooling Sites to Generate Analysis Centers  
Subjects from low enrolling sites will be pooled in order to generate analysis centers . The minimum number of 
subjects per  analysis center  is 10.  For sites with <[ADDRESS_740523] 10 
subjects.  All analyses that are controlled  for site will  use this analysi s center  designation.  Site poolability  will 
also be assessed  as described  in Sections 10.3.1  and 10.3.2 . Full details  will be  provided  in th e SAP. 
10.3.4  Handling of Missing Data for the Co -Primary Efficacy Endpoints  in the ITT Population  
For both HDSM- Ax-7 and GSP, multiple imputations for missing  values in the vehicle group will be performed 
assum ing MAR .  For the sofpi[INVESTIGATOR_519654], 15% group , multiple imputations using the CBI model will be 
employed as the primary imputation method to handle missing data.  This approach will  adopt a missing not at 
random (MNAR) assumption and missing values in the sofpi[INVESTIGATOR_519654], 15%, group will be imputed 
based on a distribution with estimated values at visits lost to follow -up similar to that of subjects in the vehicle 
group. This approach further assumes that for the treatment effect observed in sofpi[INVESTIGATOR_519654], 15% 
arm, subjects with missing data gradually trends towards the estimated mean in the vehicle group, i.e., any 
treatment benefit gained is not immediately lost upon withdrawal. The sam e co-primary analysis models will be 
applied to the multiple imputed datasets and the results combined via Rubin‚Äôs rules ( Rubin, 1976 ).  
Furthermore, in order to ensure that the missing data imputation method proposed is robust to outliers  for the 
GSP co -primary endpoint , data from subject s that meet the criterion for being an outlier will  be removed  from the 
imputation sampling database as follows . Combining the Vehicle and sofpi[INVESTIGATOR_519654], 15% arms, the 
mean and standard deviation will be calculated for the non- missing GSP change from baseline to EOT data. Data 
values more than [ADDRESS_740524] deviation will be re-calculated to see if any 
additional outliers are identified. This process will be repeated until no more outliers are identified. Prior to 
performing imputation for missing GSP change from baseline data in the ITT population, data values 
contributing to the outlying observations will be removed from the imputation sampling database, i.e. the non-
missing vehicle data. With this approach, outlying data will not be propagated during missing data imputation. 
Once an imputation is complete, all original non -missing data and the imputed, previously missing data will be 
used for the GSP ITT analysis.  Further details for this approach will be included in the SAP.  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 53 of 102 
CONFIDE NTIAL                06 AUG 2020  
10.3.5  Sensitivity Analyses of the Co -Primary Efficacy Endpoints  
To further explore the robustness of the primary analysis results  to different missing data assumptions, analyses 
using t wo additional imputation methods will be performed as presented below.  Furthermore, the ranked GSP 
and non- rank transform ed GSP  ANCOVA  analyses will be repeated  without imputing missing data, and again 
after removing outlier data. Additionally, the 7 items in the HDSM -Ax-7 scale will be analyzed individually to 
support the primary analysis for this co-primary endpoint.  
Summary of Sensitivity Analyses  of the Co -Primary Efficacy  Endpoints  
 Co-Primary Efficacy Endpoint  Assessed Sensitivity Analysis  
1 GSP change from baseline  to EOT  Analysis performed on available data 
only without imputing missing data ; 
using both ranked and non-ranked data.  
2 GSP change from baseline  to EOT  Subjects w ith outlying data removed  
from analysis ; using both ranked and 
non-ranked data  (multiple imputations 
for missing data) . 
3 HDSM -Ax-7 2- point improvement  from baseline 
to EOT  Missing data imputed as failure /non-
response  (single imputation only)  
4 HDSM -Ax-7 2- point improvement and GSP  
change from baseline  to EOT  Tippi[INVESTIGATOR_18275]  (multiple 
imputations for missing data)  
5 HDSM -Ax-7 2- point improvement  from baseline 
to EOT  Analysis of the 7 individual items in 
the HDSM -Ax-7 scale  (multiple 
imputations for missing data)  
Unless otherwise specified, sensitivity analyses  pertain to the primary analyses for the co -primary endpoints only.  
A brief description of each sensitivity analysis is provided below; c omplete details  will be included in the final 
SAP.  
Sensitivity Analysis 1: To further investigate the robustness of the GSP co-primary efficacy endpoint, the ranked 
and non- rank transformed GSP analyses will be repeated on all available data only without imputing missing 
data. The methodology will be similar to the primary analysis of the GSP co-primary endpoint.  
Sensitivi ty Analysis 2: To further investigate the robustness of the GSP co-primary efficacy outcome, the ranked 
and non- rank transformed GSP analyses will be repeated after removing outlier data (as defined in Section 
10.3.4 ). The methodology will be similar to the primary analysis of the GSP co -primary endpoint, except that 
outlier data will be removed from the imputed database for these analyses . 
Sensitivity Ana lysis 3: Missing post- baseline HDSM -Ax-7 data will be imputed as failure/non -response in both 
treatment groups. The co- primary efficacy HDSM -Ax-7 analysis will be re -run on the so-imputed HDSM -Ax-7 
dataset and treatment success proportion estimates will be  produced.   
Sensitivity Analysis 4: A tippi[INVESTIGATOR_563631]- primary 
efficacy outcomes. Tippi[INVESTIGATOR_563632]- Ax-7 and GSP co -primary 
endpoints. 
For the G SP co -primary endpoint, missing data in the vehicle arm will be assumed to be MAR, while missing 
data from the sofpi[INVESTIGATOR_519654], 15%, arm will be imputed assuming that subjects with missing data have 
missing GSP data that are worse by a prespecified  «ªFRPSDUHGWRVLPLODUVXEMHFWVZLWKREVHUYHGGDWD0LVVLQJ
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 54 of 102 
CONFIDE NTIAL                06 AUG 2020  
YDOXHVZLOOEHPXOWLSO\LPSXWHGYLDWKLVPHWKRGZLWKLQFUHDVLQJ«ªYDOXHV$«ªLQFUHPHQWRIPJZLOOEHXVHGIRU
this study. The GSP co -primary efficacy outcome analysis methodology will be applied to the imputed datasets 
and repeated until statistical significance no longer holds. The tippi[INVESTIGATOR_563633].  
For the HDSM -Ax-7 co-primary endpoint, identical imputation methodology to tha t described above for the GSP 
will be applied to the HDSM -Ax-7 total scores, and the resulting values will be dichotomized into responders 
versus non-responders using the 2-point improvement criterion . $«ªLQFUHPHQWRI on a 0- 4 scale) will be 
used for this study. The HDSM -Ax-7 co-primary efficacy outcome analysis methodology will be applied to the 
imputed datasets and repeated until statistical significance no longer holds. The tippi[INVESTIGATOR_563634]. 
Sensitivity Analysis 5: A sensitivity analysis will be conducted to investigate whether any of the individual 
items in the HDSM -Ax-[ADDRESS_740525] a 2 -point improvement in the individual question from baseline to 
EOT. The logistic regression model for the primary analysis for HDSM- Ax-7 will be repeated for each of the 7 
individual items, and each individual question will be analyzed separately. Secondly, one of the 7 items will be 
omitted, and the HDSM- Ax-7 total score will be calculated as the average of the remaining 6 items. The primary 
logistic regression analysis for 2 -point improvement response rate will be performed on thi s 6-item scale. This 
process will be repeated 7 times, each time with a different item of the HDSM -Ax-7 scale removed from 
calculation of the overall score.  
10.3.6  Analysis of the Secondary Efficacy Endpoints  
A gated, fixed -sequence testing procedure will be used  in this protocol to control the overall familywise false 
positive error rate for the primary and secondary endpoints analyses. As described above, the primary analysis 
will be regarded as positive and the tr ial will be successful for the co -primary effica cy endpoints if both null 
hypotheses in Section 10.3.1  and Section 10.3.2  of no difference are rejected in favor of sofpi[INVESTIGATOR_519654], 
15% at the 2-sided 0.05 level of significance. 
If both co-primary analyses yield statistically significant result s in favor of the sofpi[INVESTIGATOR_519654], 15% 
group, the three secondary efficacy endpoints specified in Section  10.2.[ADDRESS_740526] been 
rejected at the 2 -sided alpha= 0.05 significance level in favor of sofpi[INVESTIGATOR_519654], 15%.     
The HDSM -Ax-[ADDRESS_740527]. All other  exploratory 
efficacy endpoints that involve a  proportion of responders will be analyzed using methods similar to what was 
described for the HDSM -Ax-7 co-primary endp oint. All other exploratory endpoints that involve a change from 
baseline to a  single timepoint will be analyzed using methods similar to what is described for the GSP co-primary  
endpoint. P-values for exploratory efficacy endpoints will be provided for descriptive purposes only and no 
formal hypothesis testing will occur.  All exploratory efficacy analyses will be based on available data and 
missing GSP and HDSM-Ax EOT data imputed. 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740528] validity 
(i.e., examination of the magnitude of correlation between the HD SM-Ax total score and key va riables such as 
Questions 4 and 5 of the HDSM -Ax-7, PGI-S, PGI-C, and GSP), stab ility, reliability, ability to detect change, 
and interpretability  of clinical trial results.  
The details regarding  psychometric analyses will be described in a separate  statistical analysis plan.  
10.[ADDRESS_740529] terms, i.e., Medical Dictionary for Regulatory Activities 
(MedDRA ) system organ c lass and preferred term. At each post -baseline visit, the number and proportion of 
subjects reporting any given TEAE will be tabulated cumulatively by [CONTACT_926]; each subject will be counted only 
once according to the worst severity reported up to the current visit. Separate tables will be constructed for (a) all 
reported TEAEs, (b) protoco l treatment -related TEAEs, (c)  serious TEAEs, (d) TEAEs leading to protocol 
treatment discontinuation  (e) protocol treatment -related serious TEAEs, (f) severe TEAEs, (g) TEAEs leading to 
dose interruption, (h) TEAEs of special interest, and (i) anticholine rgic TEAEs . 
At each visit, local tolerability assessments  will be descriptively summarized by [CONTACT_926]. For any symptoms, 
subject severity is the worst severity of the two axillae.  
An overall summary table will also be presented with subject incidences tab ulated according to the worst severity 
experienced while on study. In addition, a t each post -baseline visit, local tolerability will be summarized as 
cumulative shift tables versus  baseline. Subject counts for each symptom will be cross- tabulated with baseline 
severity according to the maximum post- baseline severity reported for either axilla up to the current visit.     
Laboratory parameters will be descriptively summarized (mean, standard deviation , median, minimum, 
maximum) for values obtained at Visi t 1 and Visit 12.  Whereas, v ital signs will be summarized in a similar 
manner at each visit.   
10.5 Sample Size  
Sample size estimation was performed for the co -primary efficacy endpoints based on the results of a Phase 2b 
study ( BBI-4000- CL-203): 
‚Ä¢ HDSM -Ax-7 resp onder analysis: 2-point improvement response rates of 29.8% and 53.7% were assumed 
for the vehicle and sofpi[INVESTIGATOR_519654], 15% arms , respectively. The power is 0.95 with 116 subjects 
per arm and a total of 232 subjects. 
‚Ä¢ GSP: using rank transformed GSP data for change from baseline to EOT, a difference of 16.6 in mean 
ranks between the vehicle and sofpi[INVESTIGATOR_519654], 15% arms, with a pooled standard deviation of 
approximately 39.5, was used for this purpose. Normal approximation yielded a sample si ze estimate of 
[ADDRESS_740530] for the GSP endpoint were used to 
estimate the above sample size a nd power for each endpoint. With approximately 300 evaluable subjects, the 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740531] (two -sided p < 0.05) for both co-
primary efficacy endpoints simultaneously is greater than 0.90 (with greater than 0.95 power for each of HDSM-
Ax-7 and GSP). 
Assuming missing data from approximately 15% of subjects, a total of [ADDRESS_740532] Entry Procedures  
11.1.1  Overview of Entry Procedures  
Subjects with hyperhidrosis as defined by [CONTACT_941] c riteria  in Sections 4.2 and 4.3 (inclusion/exclusion criteria) will be 
considered for entry into this study. 
11.1.[ADDRESS_740533] also give Authorization for Use 
and Release of Health and Research Study Information and other written documenta tion in accordance with the 
relevant country and local privacy requirements (where applicable) prior to any study- related procedures or 
change in treatment.  
11.1.[ADDRESS_740534] screening number composed of a 1- digit study 
number (2 ), a 3-digit site number , followed by a 4-digit sequent ially assigned number starting at 0001, at each 
site. For instance , the first subject from site [ADDRESS_740535] screening number; 
the subsequent subject from this site will have [ADDRESS_740536] 20020001 as their assigned subjec t screening number; the subsequent subject 
from this site will have  [ADDRESS_740537] throughout the study. 
The randomization for this study will be stratified by [CONTACT_274311]. Therefore, each site will be treated as a 
block and a randomization schedule will be prepared in order to balance the 1:1 treatment assignment within the 
site. Randomization details, including block size, will be prespecified in a randomization plan. 
After subjects qualify for the study ( as determined by [CONTACT_941] I nvestigator at the Screening/Rescreening  Visit s), they 
will be randomized to sofpi[INVESTIGATOR_519666], 15% or vehicle gel, and notified that their screening number 
becomes t heir post- randomization subject number. Each kit carton will contain a treatment plastic pump, which 
will be lab eled with a unique bottle number displayed on the label.  A kit will be selected from inventory and 
dispensed to the subject after the proper prep/priming  operation (see Section  5.2). 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740538] source document. 
Approximately 350 subjects will be randomized to receive either sofpi[INVESTIGATOR_519654], 15%, or vehicle gel 
(placebo) in a ratio of 1:[ADDRESS_740539] -baseline visit, the following activities will occur to ensure compliance with the protocol:  
‚Ä¢ Subject s will be asked whether they have used the investigational product as instructed. 
‚Ä¢ Subjects will be reminded to perform ONE FULL pump actuation and use the gel expressed  per 
application to each axilla and asked whether they experienced any problems dispensing the investigational 
product. 
‚Ä¢ Subjects will be asked whether they used any other products on their axillae . 
‚Ä¢ Site staff will review concomitant medication use since the previous visit and determine whether any 
concomitant medication use qualifies as a protocol deviation   
‚Ä¢ At each post -baseline visit until EOT, site staff will collect the dispensing container from the subject , then 
weigh  and record the weight of the used container. 
11.[ADDRESS_740540] notifying the Sponsor and 
discussing the reason(s) for stoppi[INVESTIGATOR_10098] . Brickell Biotech, Inc . may stop the study with appropriate 
notification.  
12 ADMI NISTRATIVE ISSUE S 
12.1 Posting of Information on Clinicaltrials.gov  
Study information from this protocol will be posted on clinicaltrials.gov before enrollment of subjects begins. 
12.2 Protection of Human Subjects  
12.2.1  Compliance with Informed Consent Regulations (US 21 CFR Part 50) and Relevant Country 
Regulations 
Written informed consent is to be obtained from each subject prior to any study -related procedures. Potential 
subjects will be screened within 45 days prior to Visit 4 (Rescreening/Baseline ) to assess their eligibility to enter 
the study. Only eligible subjects with axillary hyperhidrosis will be enrolled.  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 58 of 102 
CONFIDE NTIAL                06 AUG 2020  
12.2.2  Compliance with  IRB Regulations 
This study is to be conducted in accordance with IRB regulations (US 21 CFR Part 56.103). The Investigator 
must obtain approval from a properly constituted IRB prior to initiating the study and re -approval or review at 
least annually . Brickell Biotech, Inc . is to be notified immediately if the responsible IRB has been disqualified or 
if proceedings leading to disqualification have begun. Copi[INVESTIGATOR_563635] I nvestigator 
must  be provided to Brickell Biotech, Inc . 
12.2.3  Compliance with  Good Clinical Practice  
This protocol is to be conducted in accordance with the applicable GCP regulations and guidelines, e.g., the ICH 
Guideline on GCP. 
12.3 Changes to the Protocol  
The I nvestigator should not implement any deviation from or changes to the protocol without approval by 
[CONTACT_563638], Inc . and prior review and documented approval/favorable opi[INVESTIGATOR_249760] a protocol 
amendment, except where necessary to eliminate immediate hazards to study subjects, or when the changes 
involve only logistical or administrative aspects of the study (e.g. , change in monitors, change of telephone 
numbers). 
12.[ADDRESS_740541]‚Äôs name [CONTACT_563677]. A subject's name [CONTACT_563678], Brickell Biotech, Inc. , the 
governing health authorities , or the FDA if they inspect the study records . Appropriate precautions will be taken 
to maintain confidentiality of medical records and personal information. 
12.4.[ADDRESS_740542] Privacy  
Written authorization and other documentation in accordance with the relevant country and local privacy 
requirements (where applicable) are  to be obtained from each subject prior to enrollment into the study, in 
accordance with the applicable privacy requirements ( e.g., HIPAA ). 
12.[ADDRESS_740543]'s medical records, hospi[INVESTIGATOR_1332], clinic charts, the Investigator's subject 
study files, as well as the results of diagnostic tests . The Investigator's copy of the CRF  serves as part of the 
Investigator‚Äô s record of a subject's study- related data .  
12.5.[ADDRESS_740544] ‚Äôs eCRF s and related 
documents. The eCRF s are to be completed  in a timely manner as defined in the clinical study agreement , or as 
otherwise specified by [CONTACT_563638] . 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/[ADDRESS_740545] privacy documentation, reco rds of the 
distribution and use of all investigational products, and copi[INVESTIGATOR_164371] s should be maintained on file. 
The Sponsor -specific essential documents should be retained until ‚â•[ADDRESS_740546] approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications in an ICH 
region or ‚â•[ADDRESS_740547]. These documents should be retained for a longer period, however, if required by [CONTACT_40006](s) or if needed by [CONTACT_1034] . 
Brickell Biotech, Inc . requires that it be notified in writing if the Investigator wishes to relinquish ownership of 
the data so that mutually agreed -upon arrangements can be made for transfer of ownership to a suitably qualified, 
responsible person.  
12.[ADDRESS_740548]  
12.6.1  Labeling/Packaging 
The investigational product will be packaged, labeled, and supplied by [CONTACT_563638], Inc. The product will be 
identified as an investigational compound for external use. The study number and a unique bottle  number will be 
identified on the unit label of the product.  
12.6.[ADDRESS_740549] should be stored at  controlled room  temperature , 68oF to 77oF (20oC to 25oC), with brief 
excursions permitted between 59¬∞F to 86¬∞F (15oC to 30oC). Maintenance of a temperature log (manual or 
automated) is required.   
12.6.[ADDRESS_740550] (used and unused) will be returned to Brickell Biotech, Inc . or its designee for 
destruction .  
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 60 of 102 
CONFIDE NTIAL                06 AUG 2020  
12.7 Monitoring by [CONTACT_1034]  
A representative of the Sponsor  will monitor the study on a periodic basis . The determination of the extent and 
nature of monitoring will be based on considerations such as the objective, purpose, design, complexity, size, and 
endpoints of the study. In the event of interruptions to site accessibility due to COVID -19 or other pandemics 
conditions, alternative means of monitoring the study documents may be implemented, as allowed by [CONTACT_563663], such as remote monitoring and/or data verification. 
Authorized representatives of Brickell Biotech, Inc . and/ or regulatory authority representatives will conduct 
on-site visits to review, audit, and copy study-related documents. These representatives will meet with the 
Investigator(s) and appropriate staff at mutually convenient times to discuss study-related data and question s. 
12.[ADDRESS_740551] joint cooperation between the Investigator and Brickell Biotech, Inc.  personnel. 
Authorship will be established  prior to the writing of the manuscript. No manuscripts regarding this study will be 
submitted without written authorization from Brickell Biotech, Inc . 
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 61 of 102 
CONFIDE NTIAL                06 AUG 2020  
13 REFERE NCES  
1. Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and sever ity in the 
[LOCATION_002]. Arch Dermatol Res . 2016;308(10):743-749. 
2. Ayele BT, Lipkovich I, Molenberghs G, Mallinckrodt CH. A Multiple -Imputation-Based Approach to 
Sensitivity Analyses and Effectiveness Assessments in Longitudinal Clinical Trials. J Biopharm Stat . 
2016;24(2):211-228.  
3. Rubin DB. Inference and missing data. Biometrika . 1976;63(3):581‚Äì590.  
4. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health 
Emergency. US Department of Health and Human Services. Food and Drug Administration. July 2020. 
FDA website.   
Sofpi[INVESTIGATOR_563572]-4000- CL-302/03 Page 62 of 102 
CONFIDE NTIAL                06 AUG 2020  
14 APPE NDICES  
 
 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 63 of 102 
CONFIDE NTIAL               06 AUG 2020  
APPE NDIX 1 :  GRAVIMETRICALLY MEASURED SWEAT 
PRODUCTIO N 
Method:  Axilla Filter Paper Gravimetric Sweat Production Measurements  
Set Up  
IMPORTA NT:  Make sure that you distinguish each gravimetric collection packet Right (R) from 
Left (L) throughout the gravimetric measurement (i.e., during set up, measurement).  
‚Ä¢ Clip or shave axilla hair if present. Use an electric razor or clippers so a short stubb le (<1  mm) is 
present (blade shaving may irritate the skin or cause folliculitis;  ok for men and women who use a 
manual razor routinely). Wash and clean the axilla to remove all loose hair or stubble. Towel dry 
the axilla( e).  
‚Ä¢ Place the subject in a room w ith controlled humidity and temperature between 20¬∞C and 25¬∞C 
(68¬∞F to 77¬∞F) for at least [ADDRESS_740552] should remain in a 
semirecumbent position.   
‚Ä¢ Measurements will be done in the same room throughout the study.  
‚Ä¢ To the best  of their ability, t he same Study Site Staff member will perform the evaluation for each 
subject both within and across subjects. If this is not possible  due to  extenuating circumstances 
(e.g., vacation, illness, etc.), another qualified Study Site Staff M ember cross -trained by [CONTACT_563664].   
‚Ä¢ Refer to the detailed study training manual and video for step -by-step directions.   
Filter Paper Measurement  
‚Ä¢ Prepare the cotton towel, filter paper , and conical tube for the assessment.    
‚Ä¢ Place one filter paper and the conical tube  with lid on  the Sponsor -provided balance sensitive to 
[ADDRESS_740553] its weight. Tare the weight of the filter paper and conical tube .   
‚Ä¢ Have subject assume a semi -reclining position with the axilla fully exposed and the arm resting 
comfortably above the head.    
‚Ä¢ Dry the axilla gently with the cotton towel.  
‚Ä¢ Using talc -free gloves, place the preweighed filter paper in the center of the axilla against the 
subject ‚Äôs skin, and have the patient carefully fold their axilla down to hold the filter paper in 
place. Immediately start the timer for 5 min utes. Immediately  after 5 minutes , ask the patient to 
lift his/her arm and gently lift the filter paper out of the axilla ry vault and place it into the conical 
tube and replace lid to avoid evaporative loss of fluid.    
‚Ä¢ Record the  time and   weight.   
‚Ä¢ Refer to detailed study training manual and video for step -by-step directions.   
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 64 of 102 
CONFIDE NTIAL               06 AUG 2020  
APPE NDIX 2:  HYPERHI DROSIS DISEASE SEVER ITY M EASURE -
AXILLA RY (HDSM -AXÔõô)¬ï YEARS OF AGE  
(VERSIO N 1.3) 
 
Hyperhidrosis  Disease  Severity  Measure --Axillary Ôõô 
(HDSM -Ax)* 
 
INSTRUCTIONS:  We are interested in finding out about your current experience with excessive 
underarm  sweating .   
‚Ä¢ Please consider excessive sweating in your underarms only  when selecting the answer to 
each question.  
‚Ä¢ For each statement, please provide the response that best describes your experience since 
you woke up yesterday . 
‚Ä¢ Please answer ALL questions even if some seem similar to others or seem irrelevant to you.  
_______________________________________________________________________________  
1. Since you woke up yesterday, how often  did you experience  the following  while  you were  
awake?   
(Please  select the number that best describes your experience.)  
 None of 
the time  A little of 
the time Some  of 
the time Most  of 
the time All of 
the time  
a) Damp  or wet clothing  caused  by [CONTACT_563665]? 0 1 2 3 4 
b) Underarm  sweating  for no apparent reason ? 0 1 2 3 4 
 
2. Since you woke up yesterday, how severe  was your e xperience  with the following?  (Please 
select the number that best describes your experience.)  
 I did not 
experience this  Mild Moderate  Severe  Very 
severe  
a) Underarm  sweating  when  you felt nervous, stressed or anxious? 0 1 2 3 4 
b) Damp or wet clothing caused by [CONTACT_563666]? 0 1 2 3 4 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 65 of 102 
CONFIDE NTIAL               06 AUG 2020  
c) Underarm  sweating  after little or no physical exercise? 0 1 2 3 4 
d) Underarm  wetness?  0 1 2 3 4 
e) Underarm  sweating  for no apparent  reason? 0 1 2 3 4 
f) Underarm  sweating  that was unmanageable? 0 1 2 3 4 
g) Underarm  sweating  when  you were  cool? 0 1 2 3 4 
 
3. Since you woke up yesterday, what was your experience with each of the following?  (Please 
select the number that best describes your experience.)  
 Not at all  Slight   Moderate Strong  Very strong a) Feeling  the need  to change  clothes  because  of underarm sweating? 0 1 2 3 4 
b) Feeling  the need  to wipe sweat  from your underarms? 0 1 2 3 4 
 
SUMMARY QUESTIONS (ANCHORS):  
4. Since you woke up yesterday, how much  of the time did you experience  excessive  underarm  
sweating  while  you were  awake?  (Please  select  the number  that best describes  your  
experience.)  
[ADDRESS_740554]  of the time 
4 All of the time 
 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/[ADDRESS_740555] since you woke up yesterday ? 
(Please  select  the number  that best describes  your  experience.)  
[ADDRESS_740556] underarm sweating (i.e., completely dry)  
1 I had underarm sweating but it was mild (i.e., slightly  damp)  
2 I had underarm sweating and it was moderate  (i.e., damp)  
3 I had underarm sweating and it was severe  (i.e., wet) 
4 I had underarm sweating and it was very severe  (i.e., soaking)  
 
6. Patient Global Impression of Severity (PGI -S) 
Please choose the response below that best describes the severity  of your underarm  
sweating over the past week .** 
0 None  
1 Mild 
2 Moderate  
3 Severe  
4 Very severe   
 
7. Patient Global Impression of Change (PGI -C) 
Please choose the response below that best describes the overall change  in your 
underarm  sweating since you started taking the study medication . ‚Ä† 
¬Ü  Very much better  
¬Ü  Moderately better  
¬Ü  A little better  
¬Ü  No change  
¬Ü  A little worse  
¬Ü  Moderately worse  
¬Ü  Very much worse  
 
* These HDSM -Ax questions can appear slightly different when administered in an electronic format.  
**Administered as Question #6 of HDSM -Ax at  each assessment  
‚Ä† Administered as Question #7 of HDSM -Ax at the Day 43 (EO T) visit only.  
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 67 of 102 
CONFIDE NTIAL               06 AUG 2020  
APPE NDIX 3:  HYPERHIDROSIS DISEAS E SEVERITY MEASURE -
$;,//$5<&+,/'¬ï 72$(<ﬁí562)$*(  
HDSM -Ax Child (version 28 FEB 2018) * 
INSTRUCTIONS:  We are interested in finding out about your  underarm  sweating .   
‚Ä¢ Circle the best answer to each question.  
o Think about sweating in your underarms only . 
o Think about your sweating this morning and yesterday . 
‚Ä¢ Please answer ALL questions.  
______________________________________________________________________  
1. Since you woke up yesterday, how often  did you have  these  things?    
 None of 
the time  A little of 
the time Some  of 
the time Most  of 
the 
time All of 
the 
time 
a) Damp  or wet clothes  from underarm  sweating? 0 1 2 3 4 
b) Underarm  sweating  for no reason ? [ADDRESS_740557] these things?  
 I did not 
have this  A tiny 
amount  A little A lot A great 
amount  
a) Underarm sweating when you felt nervous, scared, or worried? 0 1 2 3 4 
b) Damp or wet clothing from underarm sweating? 0 1 2 3 4 
c) Underarm  sweating  after sitting  quietly? 0 1 2 3 4 
d) Underarm  wetness?  0 1 2 3 4 
e) Underarm  sweating  for no reason?  0 1 2 3 4 
f) Underarm  sweating  that you could  not hide? 0 1 2 3 4 
g) Underarm  sweating  when  you were  not hot? 0 1 2 3 4 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 68 of 102 
CONFIDE NTIAL               06 AUG 2020  
 
3. Since you woke up yesterday, how much did you want to do these things?  
 Not at all  A tiny 
amount   A little A lot A great 
amount  
a) Change  clothes  because  of underarm  sweating? 0 1 2 3 4 
b) Wipe  sweat  from your underarms ? [ADDRESS_740558]  underarm  sweating?   
[ADDRESS_740559] since you woke up yesterday ?  
[ADDRESS_740560] underarm sweating  
1 I had a tiny amount of underarm sweating  
2 I had some underarm sweating  
3 I had a lot of underarm sweating  
4 I had a great amount of underarm sweating  
 
 
6. Patient Global Impression of Severity (PGI -S) 
Please choose the response below that best describes the severity of your underarm 
sweating over the past week .** 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 69 of 102 
CONFIDE NTIAL               06 AUG 2020  
 
¬Ü  None  
¬Ü  Mild 
¬Ü  Moderate  
¬Ü  Severe  
¬Ü  Very severe  
 
7. Patient Global Impression of Change (PGI -C) 
Please choose the response below that best describes the overall change in your 
underarm sweating since you started taking the study medication . ‚Ä† 
 
¬Ü  Very much better  
¬Ü  Moderately better  
¬Ü  A little better  
¬Ü  No change  
¬Ü  A little worse  
¬Ü  Moderately worse  
¬Ü  Very much worse  
* These HDSM -Ax questions can appear slightly different when administered in an electronic format.  
**Administered as Question #6 of HDSM -Ax at each assessment  
‚Ä† Administered as Question #7 of HDSM -Ax at the Day 43 (EOT) visit only  
 
 
 
  
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 70 of 102 
CONFIDE NTIAL               06 AUG 2020  
APPE NDIX 4:  DERMATOLOGY LIFE QUALITY INDEX -AXILLA; 
FOR SUBJECTS  ‚â•[ADDRESS_740561] week, how itchy, sore, painful or stinging has your underarm  skin been?  Very much ¬à A lot ¬à A little ¬à Not at all ¬à   2. Over the last week, how embarrassed or self-conscious  have you been because of your 
underarm  sweating ? Very much ¬à A lot ¬à A little ¬à Not at all ¬à   3. Over the last week, how much has your underarm sweating  interfered with you going shoppi[INVESTIGATOR_563636] ?  Very much ¬à A lot ¬àA little ¬àNot at all ¬àNot relevant ¬à  4. Over the last week, how much has your underarm sweating  influenced the clothes you wear?  Very much ¬à A lot ¬à A little ¬à Not at all ¬à Not relevant ¬à
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/[ADDRESS_740562] week, how much has your underarm sweating  affected any social  or leisure  activities?  Very much ¬à A lot ¬à A little ¬à Not at all ¬à Not relevant ¬à  6. Over the last week, how much has your underarm sweating  made it difficult for you to do any sport ? Very much ¬àA lot A little  
Not at all  
Not relevant  ¬à¬à
¬à
¬à  7. Over the last week, has your underarm sweating prevented you from working  or studying ? Yes ¬à No ¬à Not relevant ¬à   If "No", over the last week how much has your underarm  sweating  been a problem at work  or 
studying ? A lot ¬à A little ¬à Not at all ¬à   8. Over the last week, how much has your underarm sweating  created problems with your partner  or 
any of your close friends or relatives ? Very much ¬à A lot ¬à A little ¬à Not at all ¬à Not relevant ¬à  
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/[ADDRESS_740563] week, how much has your underarm sweating  caused any sexual difficulties ? Very much ¬à A lot ¬à A little ¬à Not at all ¬à Not relevant ¬à  10. Over the last week, how much of a problem has the treatment  for your underarm  sweating  been, for 
example by [CONTACT_80243], or by [CONTACT_563667]?  Very much ¬à A lot ¬à A little ¬à Not at all ¬à Not relevant ¬à 
Please check that you have answered EVERY question. Thank you.  
AY Finlay, GK Khan, April [ADDRESS_740564] not be copi[INVESTIGATOR_78437].  
 
 
 
  
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 73 of 102 
CONFIDE NTIAL               06 AUG 2020  
APPE NDIX 5:  TOLERABILITY ASSESSME NTS 
 
These assessments are to be performed for each axilla individually. The designation of ‚ÄúRight Axilla‚Äù 
or ‚ÄúLeft Axilla‚Äù in the source documents and eCRFs refers to the subject‚Äôs right and left axilla 
respectively in all cases.  Subject assessments are to be performed prior to Investigator assessments.  
Local Tolerability (Subject):  As reported by [CONTACT_519715], the severity of any 
symptoms of burning, stinging , or itching at the application -site within the previous 24 hours , and 
further any such symptoms persisting longer than 1 hour following study drug application , will be 
described specifically by [CONTACT_519716]:  Score Burning Stinging Itching 0 = Absent  Normal, no discomfort  Normal, no discomfort  Normal, no discomfort  
1 = Minimal  An awareness, but no 
discomfort  An awareness, but no 
discomfort  An awareness, but no 
discomfort  
2 = Mild  Noticeable discomfort causing intermittent awareness Noticeable discomfort causing intermittent awareness Noticeable discomfort causing intermittent awareness 3 = Moderate  Noticeable discomfort causing continuous awareness Noticeable discomfort causing continuous awareness Noticeable discomfort causing continuous awareness 4 = Severe  Definite discomfort causing continuous 
awareness, interfering 
occasionally with normal daily activities Definite discomfort causing continuous 
awareness, interfering 
occasionally with normal daily activities Definite discomfort causing continuous 
awareness, interfe ring 
occasionally with normal daily activities Local tolerability (Investigator):  The Investigator will assess the drug  application site for the 
existence of significant local symptoms. Significant local symptoms are defined as those not ordinarily 
observed following application of a topi[INVESTIGATOR_119029]. The following standardized scales will be used to 
describe specifically th e severity of any erythema or scaling:  
Score  Scaling  Erythema  
0 = Absent  No scaling  No redness  
1 = Minimal  Fine scaling, barely perceptible  Faint red or pi[INVESTIGATOR_22766], barely perceptible  
2 = Mild  Slight scaling, noticeable only with light scratching  Light red or pi[INVESTIGATOR_22766]  
3 = Moderate  Definitely noticeable scaling  Medium red coloration  
4 = Severe  Extensive scaling  Beet red coloration  
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 74 of 102 
CONFIDE NTIAL               06 AUG 2020  
APPE NDIX 6:  STUDY DRUG APPLICATI ON & SUBJECT 
INSTRUCTIO NS 
 
Apply the investigational product every day, at night prior to bedtime as follows:  
1. Expose the underarm areas and ensure they are dry. Do  not wash the underarm areas for at least 
[ADDRESS_740565] to dry for 5 minutes before putting any clothes on the upper body.  
Important information:  
‚Ä¢ The subject should sleep in a T -shirt or similar pajama to avoid touching the underarm area while 
sleepi[INVESTIGATOR_007].  
‚Ä¢ Subjects should maintain their underarm areas grooming habits  as follows:    
o Do not shower, shave, or wash the underarm area for at least [ADDRESS_740566].  
‚Ä¢ Subjects should not apply any other product to the axillary area (including  Sponsor -provided 
non-antiperspi[INVESTIGATOR_563637]) for at least [ADDRESS_740567] application.  
‚Ä¢ The subject should use the applicator provided to avoid contact [CONTACT_563668]. Special 
care should be taken to avoid contact [CONTACT_519713]. Of note, hands should be 
washed after applying the gel to avoid possible skin and eye contact [CONTACT_563651].  
‚Ä¢ The study product cont ains alcohol and is fla mmable. The subject should avoid fire, flame s, or 
smoking during the application and until the gel has dried. The subject should not expose the 
container to fire, flame s, or extreme heat.  
 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 75 of 102 
CONFIDE NTIAL               06 AUG 2020  
On the day of all clinic study visits you may shower but are NOT pe rmitted to:  
‚Ä¢ Apply any product to your axilla (including Sponsor -provided non-antiperspi[INVESTIGATOR_563637]).  
‚Ä¢ Exercise . 
‚Ä¢ Consume  caffeine containing food or beverage  until the gravimetric assessments are completed . 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/[ADDRESS_740568] any questions:  
Contact:        [CONTACT_229803]:     
If you participate in  this study, you will be expected to:  
‚Ä¢ Follow the instructions you are given  and c ome to the study center for all visits with the study 
doctor or study staff.  
‚Ä¢ Tell the study doctor or study staff about any changes in your health or the way you feel.  
‚Ä¢ Tell the study doctor or study staff if you want to stop being in the study at any time.  
‚Ä¢ Apply the study product each evening before bedtime.  
‚Ä¢ Not shower, shave, or wash the underarm area for at least [ADDRESS_740569] application.  
‚Ä¢ Not shave underarm a rea at least [ADDRESS_740570] in the evening.  
‚Ä¢ Do not apply any other product to the axillary area (including  Sponsor -provided non-antiperspi[INVESTIGATOR_563615]) for at least [ADDRESS_740571] application.  
‚Ä¢ Be careful not to touch  your eyes or mouth with the gel or with your hands while applying the gel.  
‚Ä¢ Use an acceptable  method of birth control throughout the entire study if you are able to become 
pregnant.  
‚Ä¢ Not breastfeed while you are in the study (for applicable females).  
‚Ä¢ Wear  a T-shirt while  sleep ing or similar pajama and avoid touching the underarm area.  
‚Ä¢ Not start any new medications or change your medications without approval from the study doctor.  
‚Ä¢ Not allow access to the study medication assigned to you to anyone beside the study staff.  
‚Ä¢ Store the study medications according to the instructions on the label.  
 
IMPORTA NT:  
‚Ä¢ The investigational product contains alcohol and is flammable.  
‚Ä¢ Avoid fire, flame s, or smoking during the application and until the gel has dried.  
‚Ä¢ Do not expose the container to fire, flame , or extreme heat.  
 
Bring your previously dispensed Study Drug container to the following clinic visits AFTER  
Visit  4 (Baseline ): Visit  7 (Day 22 ) and Visit 12  (End of Treatment ; Day 43 ).  
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 77 of 102 
CONFIDE NTIAL               06 AUG 2020  
APPE NDIX 7:  PROTOCO L AME NDME NTS 
 
AME NDME NT 01 SUMMAR Y OF CHA NGES  Change Number Section # / Name [CONTACT_563679] 1 All pages of protocol  Header: Added the version number to the protocol number /01 (Protocol BBI -4000 -CL-302/01 on all 
pages  
 Footer: Added the amendment date to all pages  Change Number Section # / Name [CONTACT_563679] 2 Title Page  Added the date of amendment   Original Text VERSIO N: Original September 27, 2019  Revised Text  ORIGI NAL PROTOCOL: September 27, 2019  AME NDME NT 01:  November 08, 2019  
 Change Number Section # / Name [CONTACT_563679] 3 SYNOPSIS,  
Inclusion Criteria  Revised text regarding acceptable contraceptive methods , duration of contraception,  and definition of postmenopausal. 
 Original Text  6.  Sexually active females of childbearing potential (FOCBP)*  who are engaging in sexual activity that 
can cause pregnancy must agree to periodic 
pregnancy testing and use a medically acceptable 
method of contraception while receiving protocol 
assigned product. This inclu des perimenopausal 
women who are less than [ADDRESS_740572] 
menses. Acceptable contraceptive methods include 
the following:  
a. Abstinence for the duration of the study, or 
where partner is sterile (e.g., vasectomy);  
b. Hormonal contraception, including oral, 
injectable, or implantable methods star ted 
¬ï2 months prior to screening; OR  
c. Two forms of non-hormonal contraception, 
including intrauterine devices ( ¬ï1-week status post placement), or properly used 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 78 of 102 
CONFIDE NTIAL               06 AUG 2020  
barrier methods (e.g., male or female condoms , cervical cap/diaphragm , 
spermicid al agents).  
 
* FO CBP for this study includes any 
premenopausal female capable of becoming 
pregnant who has not undergone successful 
surgical sterilization (hysterect omy, 
ELODWHUDOWXEDOOLJDWLRQ>¬ï 6 months prior to 
baseline] or bilateral oophorectomy) or is 
not postmenopau sal (defined as amenorrhea 
¬ïFRQVHFXWLYHPRQWKV  LQZRPHQ¬ï
years of age).  
 Revised Text  6.  Sexually active females of childbearing potential (FOCBP)* who are engaging in sexual activity that 
can cause pregnancy must agree to periodic 
pregnancy testing and use a medically acceptable 
method of contraception for the duration of the 
study. This inclu des perimenopausal women who 
are less than [ADDRESS_740573] menses. 
Acceptable contraceptive methods include the 
following:  
a. Abstinence for the duration of the study, or 
where partner is sterile (e.g., vasectomy); 
OR 
b. Hormonal contraception, including oral, 
injectable, or implantable methods started 
¬ïPRQWKVSULRUWRVFUHHQLQJ25  
c. Non-hormonal contraception, including 
LQWUDXWHULQHGHYLFHV¬ï -week  status post 
placement), or properly used barrier 
methods (e.g., male or female condoms with 
or without spermicide, cervical 
cap/diaphragm with spermicide).  
 
* FOCBP for this study includes any 
premenopausal female capable of becoming 
pregnant who has not undergone successful 
surgical sterilization (hysterect omy, 
ELODWHUDOWXEDOOLJDWLRQ>¬ï 6 months prior to 
baseline] or bilateral oophorectomy) or is 
not postmenopausal (defined as amenorrhea 
¬ïFRQVHFXWLYHPRQWKV  
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 79 of 102 
CONFIDE NTIAL               06 AUG 2020  
 Change Number Section # / Name [CONTACT_563679] 4 SYNOPSIS, Study Design Revised the number of clinical sites from 80 to 65  Original Text  Approximately 450 subjects, at approximately 80 
clinical sites in the [LOCATION_002] will be 
randomized to receive either sofpi[INVESTIGATOR_519673], 15% or vehicle gel (placebo) in a balanced 1:1 
ratio in order to obtain approximately 406 
evaluable subjects at the end of study.  
 Revised Text  Approximately 450 subjects, at up to approximately 
65 clinical sites in the [LOCATION_002], will be 
randomized to receive either sofpi[INVESTIGATOR_519673], 15% or vehicle gel (placebo) in a balanced 1:1 
ratio in order to obtain approximately 406 
evaluable subjects at the end of study.  
 Change Number Section # / Name [CONTACT_563679] [ADDRESS_740574] of assessments.  Original Text  Gravimetric measurements of sweat production and 
patient -reported outcomes HDSM -Ax-7, 
Hyperhidrosis Quality of Life Index, and 
Dermatology Life Quality Index (DLQI) (via 
electronic clinical outcomes assessment [eCOA] 
technology) will be recorded during the study at 
predefined time points.   Revised Text Gravimetric measurements of sweat production and 
patient -reported outcomes HDSM -Ax-7 and 
Dermatology Life Quality Index (DLQI) (via 
electronic clinical outcomes assessment [eCOA] 
technology) will be recorded during the study at 
predefined time points.  
 Change Number Section # / Name [CONTACT_563679] [ADDRESS_740575] 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 80 of 102 
CONFIDE NTIAL               06 AUG 2020  
 Change Number Section # / Name [CONTACT_563679] [ADDRESS_740576] the change in number of clinical sites from 80 to 65  Original Text  Approximately 450 subjects  at 80 clinical sites in 
the US will be enrolled to obtain approximately 406 
evaluable subjects at the end of study.   Revised Text Approximately 450 subjects, at up to approximately 
65 clinical sites in the US, will be enrolled to obtain 
approximately 406 evalu able subjects at the end of 
study.  
 Change Number Section # / Name [CONTACT_563679] [ADDRESS_740577] the change in number of clinical sites from 80 to 65  Original Text  Approximately 450 subjects, at approximately 80 
clinical sites, will be randomized to receive either 
sofpi[INVESTIGATOR_519654], 15% or vehicle gel in a 
1:1 ratio to obtain approximately 406 evaluable 
subjects at the end of study.   Revised Text Approximately 450 subjects, at up to approximately 
65 clinical sites, will be randomized to receive 
either sofpi[INVESTIGATOR_519654], 15% or vehicle gel 
in a 1:1 ratio to obtain approximately 406 evaluable 
subjects at the end of study.  
 Change Number Section # / Name [CONTACT_563679] 9 Section 4.2 , 
Inclusion Criteria  Revised text regarding acceptable contraceptive methods , duration of contraception,  and definition of postmenopausal.  Original Text  6.  Sexually active females of childbearing potential (FOCBP)* who are engaging in sexual activity that 
can cause pregnancy must agree to periodic 
pregnancy testing and use a medically acceptable 
method of contraception while receiving protocol 
assigned produc t. This inclu des perimenopausal 
women who are less than [ADDRESS_740578] menses. Acceptable contraceptive methods include 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 81 of 102 
CONFIDE NTIAL               06 AUG 2020  
the following: a. Abstinence for the duration of the study, or 
where partner is sterile (e.g., vasectomy);  
b. Hormonal contraceptio n, including oral, 
injectable, or implantable methods started 
¬ï2 months prior to screening; OR  
c. Two forms of non -hormonal contraception, 
including intrauterine devices (IUD; ¬ï[ADDRESS_740579] placement), or properly 
used barrier methods (e.g., male or fem ale 
condoms, cervical cap/diaphragm, 
spermicidal agents).  
*  FOCBP for this study includes any 
premenopausal female capable of becoming 
pregnant who has not undergone successful 
surgical sterilization (hysterectomy, 
ELODWHUDOWXEDOOLJDWLRQ>¬ïPRQWKVSULR r to 
baseline] or bilateral oophorectomy) or is 
not postmenopausal (defined as amenorrhea 
¬ïFRQVHFXWLYHPRQWKVLQZRPHQ¬ï
years of age).   
Revised Text 6.  Sexually active females of childbearing potential (FOCBP)* who are engaging in sexual activity that 
can cause pregnancy must agree to periodic 
pregnancy testing and use a medically acceptable 
method of contraception for the duration of the 
study. This inclu des perimenopausal women who 
are less than [ADDRESS_740580] menses. 
Acceptable contra ceptive methods include the 
following:  
a. Abstinence for the duration of the study, or 
where partner is sterile (e.g., vasectomy); 
OR 
b. Hormonal contraception, including oral, 
injectable, or implantable methods started 
¬ï2 months prior to screening; OR  
c. Non-hormo nal contraception, including 
intrauterine devices (IUD; ¬ï[ADDRESS_740581] placement), or properly used barrier 
methods (e.g., male or female condoms with 
or without spermicide, cervical 
cap/diaphragm with spermicide).  
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 82 of 102 
CONFIDE NTIAL               06 AUG 2020  
*  FOCBP for this study includes any  
premenopausal female capable of becoming 
pregnant who has not undergone successful 
surgical sterilization (hysterectomy, 
ELODWHUDOWXEDOOLJDWLRQ>¬ïPRQWKVSULRUWR
baseline] or bilateral oophorectomy) or is 
not postmenopausal (defined as amenorrhea 
¬ï12 consecutive months).  
 Change Number Section # / Name [CONTACT_563679] [ADDRESS_740582] changes regarding acceptable contraceptive methods and definition of postmenopausal.  Original Text  12.FOCBP for this study includes any premenopausal female capable 
of becoming pregnant who has not undergone successful surgical 
VWHULOL]DWLRQK\VWHUHFWRP\ELODWHUDOWXEDOOLJDWLRQ>¬ïPRQWKVSULRU
to baseline], or bilateral oophorectomy) or is not postmeno pausal 
GHILQHGDVDPHQRU[LOCATION_006]HD¬ïFRQVHFXWLYHPRQWKVLQZRPHQ¬ï\HDUV
of age).   Revised Text 12.FOCBP for this study includes any premenopausal female capable 
of becoming pregnant who has not undergone successful surgical 
sterilization (hysterectomy, bi ODWHUDOWXEDOOLJDWLRQ>¬ïPRQWKVSULRU
to baseline], or bilateral oophorectomy) or is not postmenopausal 
GHILQHGDVDPHQRU[LOCATION_006]HD¬ïFRQVHFXWLYHPRQWKV  
 Change Number Section # / Name [CONTACT_563679] 11 Section 8.1.3, Clinical Laboratory 
Assessments  Additional assessments added to the Routine Urinalysis Table , and specific gravity grouped with 
these additional assessments   Original Text  pH, glucose, protein, blood and ketones by [CONTACT_563669], color, appearance, glucose, ketones, 
leukocyte esterase, nitrite, occult blood, pH, 
protein, specific gravity, and urobilinogen   
 Change Number Section # / Name [CONTACT_563679] [ADDRESS_740583] changes to the definition of postmenopausal  
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 83 of 102 
CONFIDE NTIAL               06 AUG 2020  
 Original Text  * Females of childbearing potential for this study 
includes any female capable of becoming pregnant 
who has not undergone successful surgical 
sterilization (hysterect omy, bilateral tubal ligation 
>¬ï6 months prior to baseline], or bilateral 
oophorectomy) or is not postmenopausal (defined 
as amenorrhea >12 consecutive months in women 
¬ï55 years of age).   Revised Text * Females of childbearing potential for this study 
includes any female capable of be coming pregnant 
who has not undergone successful surgical 
sterilization (hysterect omy, bilateral tubal ligation 
>¬ï6 months prior to baseline], or bilateral 
oophorectomy) or is not postmenopausal (defined 
as amenorrhea ¬ï12 consecutive months).  
 Change Number Section # / Name [CONTACT_563679] [ADDRESS_740584] 
Dermatitis (Skin 
Sensitization) Assessment Added new section to include allergic contact [CONTACT_563670] # / Name [CONTACT_563679] [ADDRESS_740585] ‚Äúeffective‚Äù to ‚Äúacceptable‚Äù when describing adequacy of contraception  Change Number Section # / Name [CONTACT_563679] [ADDRESS_740586]. This includes perimenopausal women who 
are <[ADDRESS_740587] menses. Acceptable contraceptive methods include the following: 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 84 of 102 
CONFIDE NTIAL               06 AUG 2020  
‚Ä¢ Abstinence for the duration of the study or 
where partner is sterile (e.g., vasectomy) is 
accep table form of contraception;  
‚Ä¢ Hormonal contraception, including oral, 
injectable, or implantable methods started 
¬ï2 months prior to screening; OR  
‚Ä¢ Two forms of non -hormonal contraception, 
including IUD ( ¬ï1-week status post 
placement) or properly used barrier  methods 
(e.g., male or female condoms, cervical 
cap/diaphragm, spermicidal agents).  
* FOCBP for this study includes any 
premenopausal female capable of becoming 
pregnant who has not undergone successful surgical 
sterilization (hysterectomy, bilateral tuba l ligation 
>¬ïPRQWKVSULRUWREDVHOLQH@RUELODWHUDO
oophorectomy) or is not postmenopausal (defined 
DVDPHQRU[LOCATION_006]HD¬ïFRQVHFXWLYHPRQWKVLQZRPHQ
¬ï\HDUVRIDJH   
Revised Text FOCBP must agree to periodic pregnancy testing and use a medically acceptable method of 
contraception for the duration of the study. This 
includes perimenopausal women who are <[ADDRESS_740588] menses. Acceptable 
contraceptive methods include the following:  
‚Ä¢ Abstinence for the duration of the study or 
where partne r is sterile (e.g., vasectomy); 
OR  
‚Ä¢ Hormonal contraception, including oral, 
injectable, or implantable methods started 
¬ï2 months prior to screening; OR  
‚Ä¢ Non-hormonal contraception, including 
IUD ( ¬ï1-week status post placement) or 
properly used barrier metho ds (e.g., male or 
female condoms with or without 
spermicide, cervical cap/diaphragm with 
spermicide).  
* FOCBP for this study includes any 
premenopausal female capable of becoming pregnant who has not undergone successful surgical 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 85 of 102 
CONFIDE NTIAL               06 AUG 2020  
sterilization (hysterectomy, bilateral tubal ligation >¬ïPRQWKVSULRUWREDVHOLQH@RUELODWHUDO
oophorectomy) or is not postmenopausal (defined 
DVDPHQRU[LOCATION_006]HD¬ïFRQVHFXWLYHPRQWKV  
 Change Number Section # / Name [CONTACT_563679] [ADDRESS_740589] both within and across 
subjects. If this is not possible due to extenuating 
circumstances (e.g., vacation, illness, etc.), another 
qualified Study Site Staff Member cross -trained by  
[CONTACT_563671].    Revised Text To the best of their ability, the same Study Site 
Staff member will perform the evaluation for each 
subject both within and across subjects. If this is 
not possible due to extenuating circumstances (e.g., 
vacation, illness, etc.), another qualified Study S ite 
Staff Member cross -trained by [CONTACT_563672].   
 Change Number Section # / Name [CONTACT_563679] 17 Appendix 7  Added new Appendix 7 to detail changes made in AMENDMENT 01 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 86 of 102 
CONFIDE NTIAL               06 AUG 2020  
AME NDME NT 02 SUMMARY OF CHA NGES  Change Number Section # / Name [CONTACT_563679] [ADDRESS_740590] changes in the sample size calculation. Corresponding text in the synopsis and 
the following sections from the main body text 
revised accordingly: Section  2, Study Design; 
Section 4.1, Number of Subjects; and Section 
11.1.3, Method for Assignment t o Study Product Groups. 
 Original Text  Based on analysis of results from a previous Phase 2b study (CL -203), the following treatment 
differences (and variation) are expected in this 
protocol for the co -primary efficacy endpoints:  
 
‚Ä¢ HDSM -Ax-7 responder analysis: an 
expected treatment difference of 23.9% with 
a reference (vehicle group) response rate of 
approximately 29.8%. However, to be 
conservative, the lower limit of a 1 -sided 
75% confidence interval for the difference 
estimate, 18%, was used for samp le size and 
power estimation.   
 
‚Ä¢ GSP: an expected mean treatment 
difference of [ADDRESS_740591] 
deviation of approximately 170. However, 
to be conservative, the lower limit of a 
1-sided 62.5% confidence inter val for the 
difference estimate, [ADDRESS_740592] for the GSP endpoint were used 
to estimate power for each endpoint. It is estimated 
that 450 total subjects will need to be randomized 
(in a 1:1 allocation) with 406 subjects completing 
the co -primary efficacy assessments (approximately 
10% drop -out rate). With [ADDRESS_740593] (two -sided p < 0.05) for both co-primary endpoints 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 87 of 102 
CONFIDE NTIAL               06 AUG 2020  
simultaneously is greater than 0.90 (with greater than 0.95 power for each of HDSM -Ax-7 and 
GSP).  
 
Additionally, sample size estimation was also 
performed using rank -transformed GSP data. A 
difference of 16.[ADDRESS_740594] deviation of approximately 42 was used 
for this purpose. This yielded a reduced sample size 
estimate compared with the target of 406 subjects 
completing the co -primary efficacy assessments in 
order to  achieve 0.95 power for GSP, further 
indicating that our sample size estimations are conservative. 
 Revised Text  Sample size estimation was performed for the co-primary efficacy endpoints based on the results of a 
Phase 2b study ( BBI-4000 -CL-203):  
 
‚Ä¢ HDSM -Ax-7 responder analysis: 2-point 
improvement response rates of 29.8% and 
53.7% were assumed for the vehicle and 
sofpi[INVESTIGATOR_519654] , 15%  arms 
respectively. The power is 0.95 with 116 
subjects per arm and a total of 232 subjects.  
 
‚Ä¢ GSP: using rank -transformed GSP data for 
change from baseline to EOT, a difference 
of 16.6 in mean ranks between the vehicle 
and sofpi[INVESTIGATOR_519654] , 15%  arms, 
with a pooled standard deviation of 
approximately 39.[ADDRESS_740595] (two -sided p < 0.05) for 
both co -primary efficacy endpoints simultaneously 
is greater than 0.90 (with greater than 0.95 power for each of HDSM-Ax-7 and GSP). 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 88 of 102 
CONFIDE NTIAL               06 AUG 2020  
 Assuming missing data from approximately 15% of 
subjects, a total of 350 subjects will be  targeted for enrollment.  Change Number Section # / Name [CONTACT_563679] 2 Section 2,  
Study Design  The number of potential sites was changed from up to 65 to up to 45, and the number of subjects in 
each treatment arm was adjusted to 175.  
Corresponding text in the synopsis and Section 4.1, 
Number of Subjects also revised.  
 Original Text  Approximately 450 subjects, at up to approximately 65 clinical sites in the US, will be enrolled to obtain 
approximately 406 evaluable subjects at the end  of 
study.  
 
Subjects will be randomized 1:1 to receive 
sofpi[INVESTIGATOR_519654], 15% or vehicle gel 
(225 subjects dosed with 15% gel and 225 subjects dosed with vehicle gel).   Revised Text  Approximately 350 subjects, at up to approximately 45 clinical sit es in the US, will be enrolled to obtain 
approximately 300 evaluable subjects at the end of 
study.  
 
Subjects will be randomized 1:1 to receive 
sofpi[INVESTIGATOR_519654], 15% or vehicle gel 
(175 subjects  dosed with 15% gel and 175 subjects dosed with vehicle gel).   
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 89 of 102 
CONFIDE NTIAL               06 AUG 2020  
AME NDME NT 03 SUMMARY OF CHA NGES  Change Number Section # / Name [CONTACT_563679] 1 SYNOPSIS, Study Objectives;  
Section 2,  
Study Design;  
Section 3, Study 
Objectives and Assessments Text was revised in multiple sections to specify primary  axillary hyperhidrosis as the indication 
throughout the protocol.   Original Text  ‚Ä¶ subjects with axillary hyperhidrosis.   Revised Text ‚Ä¶subjects with primary axillary hyperhidrosis.  Change Number Section # / Name [CONTACT_563679] [ADDRESS_740596] answer all of the 7 sub items to be evaluable for the HDSM-Ax-7 scale assessment.  Revised Text  For each of the HDSM-Ax sub-items, missing values at EOT will be imputed. HDSM -Ax-7 at EOT will be derived from the imputed values.  Change Number Section # / Name [CONTACT_563679] 3 SYNOPSIS, Statistical Methods, Efficacy Details were added regarding normality testing and the use of rank -transformed versus continuous GSP 
data.  
 Original Text  The GSP co-primary endpoint will be analyzed using a rank based analysis of covariance 
(ANCOVA)  model with  fixed effects for treatment, baseline ranked GSP, and analysis center.  Revised Text  The GSP co-primary endpoint will be analyzed using an analysis of covariance (ANCOVA) model 
with fixed effects for treatment, baseline ranked 
GSP, and analysis center. The ANCOVA may use 
rank-transformed or continuous data, pending the 
outcom e of the Shapi[INVESTIGATOR_563587]. The 
normality test will be performed prior to multiple 
imputation and separately for each arm. Should the normality assumption be violated for either arm, the 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 90 of 102 
CONFIDE NTIAL               06 AUG 2020  
primary analysis will use rank-transformed GSP data. If the  normality assumption hold s for both 
arms, the primary analysis will use continuous GSP 
data.  
 Change Number Section # / Name [CONTACT_563679] 4 SYNOPSIS, Statistical Methods,  Safety Additional TEAE tables were included in the safety analyses.  
 Original Text  Separate tables will be constructed for (a) all reported TEAEs, (b) protocol treatment -related 
TEAEs, (c) serious TEAEs, and (d) TEAEs leading to protocol treatment discontinuation,  Revised Text  Separate tables will be constructed for (a) all reported TEAEs, (b) protocol treatment -related 
TEAEs, (c) serious TEAEs, (d) TEAEs leading to 
protocol treatment discontinuation, (e) protocol 
treatment -related serious TEAEs, (f) severe 
TEAEs, (g) TEAEs leading to dose interruption, (h) 
TEAEs of specia l interest, and (i) anticholinergic TEAEs.    Change Number Section # / Name [CONTACT_563679] [ADDRESS_740597] (two -sided p < 0.05) for 
both co -primary efficacy endpoints simultaneously 
is greater than 0.90 (with greater than 0.95 power 
for each of HDSM -Ax-7 and GSP).  
Assuming missing data from approximately 15% of 
subjects, a total of [ADDRESS_740598] for the GSP endpoint were u sed 
to estimate the above sample size and power for each endpoint. With approximately 300 evaluable 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/[ADDRESS_740599] (two -sided 
p < 0.05) for both co -primary efficacy endpoints 
simultaneously is greater than 0.90 (with greater 
than 0.95 power for each of HDSM -Ax-7 and 
GSP).  
Additionally, sample size estimation was also 
performed using non-rank-transformed GSP data. 
An expected mean treatment difference  of [ADDRESS_740600] deviation of approximately 
170 was used for this purpose. This yielded a 
reduced sample size estimate compared with the 
target of 300 subjects completing the co -primary 
efficacy assessments in order to achieve 0.95 power 
for GSP, further indicating tha t our sample size 
estimations are conservative.  
Assuming missing data from approximately 15% of 
subjects, a total of 350 subjects will be targeted for 
enrollment.  
 Change Number Section # / Name [CONTACT_563679] [ADDRESS_740601] exposures; additionally, text was 
deleted pertaining to previously ongoing studies, 
which have now been completed.  
 Change Number Section # / Name [CONTACT_563679] 7 Section 7, 
Procedures  Text was added following the introductory paragraphs in Section 7 to specify that some 
assessments may be conducted remotely due to COVID-19-related restrictions.  Revised Text  In the event of restrictions due to COVID-19, or any other pandemic, the Sponsor may, with IRB 
approval where required, during the study 
implement some or all study assessments and 
procedures associated with patient visits to be 
conducted remotely or by [CONTACT_537141] (per FDA 
Guidance on Conduct of Clin ical Trials of Medical 
Products during COVID -19 Public Health Emergency, March 2020) when the patients‚Äô ability 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 92 of 102 
CONFIDE NTIAL               06 AUG 2020  
to visit investigator sites is impacted.   Change Number Section # / Name [CONTACT_563679] [ADDRESS_740602] 
answer all of the 7 sub -items to be evaluable for the 
HDSM -Ax-7 endpoint. Data will be considered missing for non-evaluable subjects.  Revised Text  The mean will be derived by [CONTACT_563673] 7 item scores and dividing it by 7. For each o f the 
HDSM -Ax sub -items, missing values at EOT will 
be imputed as described briefly in Section 10.3.1. 
HDSM -Ax-7 at EOT will be derived from the 
imputed values. Further details on imputation methods will be provided in the SAP.  Change Number Section # / Name [CONTACT_563679] 9 Section 10.2.4, Exploratory Efficacy 
Endpoints  Additional exploratory endpoints were included.  Revised Text  ‚Ä¢ The proportion of subjects achieving at least a 2-point improvement in the HDSM -Ax 
Question 4 score from baseline to Days 8, 15, 
22, 29, 36, 41, 42, 43 (EOT), and 57.  
‚Ä¢ The proportion of subjects achieving at least a 
1-point improvement in the HDSM -Ax 
Question 5 score from baseline to Days 8, 15, 
22, 29, 36, 41, 42, 43 (EOT), and 57.  
 Change Number Section # / Name [CONTACT_563679] 10 Section 10.3, 
Analysis Methods  Text was added specifying that missing values will be imputed.  
 Original Text  The primary efficacy analysis will be performed on the ITT population.  
 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 93 of 102 
CONFIDE NTIAL               06 AUG 2020  
 Revised Text  The primary efficacy analysis will be performed on the ITT population with missing values imputed.  
 
 Change Number Section # / Name [CONTACT_563679] [ADDRESS_740603] is missing Visit 4 (Day 1) value, Visit 1 (Screening) value will be used as Baseline. If a 
subject is missing Day [ADDRESS_740604] (in 
time) available non -missing HDSM -Ax-7 value 
from Day 41 (¬±2 days) or Day 42 (¬±2 days) will be 
used as t he first level of imputation. Should none of 
the Days  41, 42, and 43 values be available, 
multiple imputations of missing EOT HDSM -Ax-7 
score will be performed on the sofpi[INVESTIGATOR_563627], 15% arm values using a control -based 
imputations (CBI) methodology ( see Sectio n 
10.3.4 ). Multiple imputations assuming missing at 
random will be performed for missing data for 
vehicle subjects.    Revised Text  Imputation will be item-level. If a subject is missing values for any of items 1a, 1b, 2a, 2b, 2c, 
2d, or 2e at Visit 4 (Day 1), the Visit 1 (Screening) 
value will be used as Baseline. If the Visit 1 
(Screening) value is also missing, the subject will 
be excluded from all HDSM -Ax-[ADDRESS_740605] (in t ime) available non -missing 
value from Day 41 (¬±2 days) or Day 42 (¬±2 days) 
will be used as the first level of imputation. Should 
none of the Days  41, 42, and 43 values be 
available, multiple imputations of missing EOT 
item-level scores will be performed on  the 
sofpi[INVESTIGATOR_519654], 15% arm values using a 
control -based imputations (CBI) methodology (see Section 10.3.4). Multiple imputations assuming 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 94 of 102 
CONFIDE NTIAL               06 AUG 2020  
missing at random will be performed for missing data for vehicle subjects. The HDSM -Ax-7 score 
will be calc ulated using the imputed item -level 
values. Further details on imputation methods will 
be provided in the SAP.    Change Number Section # / Name [CONTACT_563679] 12 Section 10.3.1, Primary and 
Secondary Analysis 
of the HDSM -Ax-7 
Co-Primary Endpoint Details regarding site poolability were added in the estimand sub -section.  
 Revised Text  In addition, a separate site poolability analysis will be performed with analysis center -by-treatment 
interaction terms added to the primary analysis 
model. An overall p < 0.[ADDRESS_740606] 
to account for the potential heterogeneity .   Change Number Section # / Name [CONTACT_563679] [ADDRESS_740607] will be performed prior to multiple 
imputation for missing data and separately for each arm. Should the normality assumption be violated 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 95 of 102 
CONFIDE NTIAL               06 AUG 2020  
for either arm, the co-primary endpoint will be analyzed using rank -transformed GSP data. If the 
normality assumption holds for both arms, then the 
co-primary endpoint will be analyzed using 
continuous GSP data.    Change Number Section # / Name [CONTACT_563679] 14 Section 10.3.2, Primary and 
Secondary Analyses 
of the GSP 
Co-Primary Endpoint Text was revised to indicate changes to the imputation method regarding the use of continuous 
or ranked data.  
 Original Text  Imputation Model: Data from subjects (see Section 10.3.3) meeting the criterion for ‚Äúoutlier‚Äù 
will be removed from imputation sampling 
database (i.e., data for vehicle patients) prior to 
missing data imputation. From the remaining 
imputation sampling database of continuous  GSP 
measurements, multiple imputations of missing 
EOT sofpi[INVESTIGATOR_519666], 15% arm GSP values 
will be performed using a CBI methodology (see 
Section 10.3.4). Multiple imputations assuming 
MAR will be performed for missing EOT data 
vehicle subjects.  
Analys is Model:  ANCOVA model (either non -
ranked or ranked, pending outcome of normality 
test) 
Fixed effects:  The following fixed effects are 
planned:  
‚Ä¢ Treatment (class effect: sofpi[INVESTIGATOR_519673], 15% group, vehicle group)  
‚Ä¢ Baseline ranked GSP  
‚Ä¢ Analysis center (see Section 10.3.3)  
 Revised Text  Imputation Model: Imputation will be done using continuous data prior to rank -transformation, 
should the normality assumption be violated. For 
continuous data, subjects with results (see Section 
10.3.3) meeting the criterion for ‚Äúoutlier‚Äù will be 
removed from imputation sa mpling database (i.e., data for vehicle patients) prior to missing data 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 96 of 102 
CONFIDE NTIAL               06 AUG 2020  
imputation. From the remaining imputation sampling database of continuous GSP 
measurements, multiple imputations of missing 
EOT sofpi[INVESTIGATOR_519666], 15% arm GSP values 
will be performe d using a CBI methodology (see 
Section 10.3.4). Multiple imputations assuming 
MAR will be performed for missing EOT data 
vehicle subjects. Further details on multiple 
imputations will be provided in the SAP.  
Analysis Model:  ANCOVA model (either non -
ranked or ranked, pending outcome of normality 
test) 
Fixed effects:  The following fixed effects are 
planned:  
‚Ä¢ Treatment (class effect: sofpi[INVESTIGATOR_519673], 15% group, vehicle group)  
‚Ä¢ Baseline GSP (either non -ranked or ranked, 
pending outcome of normality test)  
‚Ä¢ Analysis center (see Section 10.3.3)  
 Change Number Section # / Name [CONTACT_563679] 15 Section 10.3.2, Primary and 
Secondary Analyses 
of the GSP 
Co-Primary Endpoint Text in (a) was revised to indicate changes to the imputation method regarding the use  of continuous 
or ranked data, and text was added to (c) regarding 
site poolability analysis.  
 Original Text  (a) Using the same methodology as described above, an ANCOVA analysis will be performed for 
either the non -rank transformed, continuous GSP 
data.  
 Revised Text  (a) Using the same methodology as described above, an ANCOVA analysis will be performed for 
either the non -rank transformed, continuous GSP 
data or the rank transformed GSP data, pending the 
results of the normality test. If the normality 
assumption is violated and the rank -transformed 
data are used as the co -primary endpoint, analysis 
of the continuous data will be supportive. If the 
normality assumption holds and the continuous data are used as the co-primary endpoint, then 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 97 of 102 
CONFIDE NTIAL               06 AUG 2020  
analysis of the rank-transformed data will be supportive.  
(b)‚Ä¶.  
(c) For the primary endpoint of either ranked or 
continuous GSP (pending normality test results), a 
separate, site poolability analysis will be performed 
with analysis center -by-treatment interaction terms 
added to the primary analysis model. An overall p 
< 0.[ADDRESS_740608] to account for the potential 
heterogeneity.    
 Change Number Section # / Name [CONTACT_563679] [ADDRESS_740609] 
10 subjects. All analyses that are controlled for site will use this analysis center designation.    Revised Text  For sites with <[ADDRESS_740610] 10  subjects. 
All analyses that are controlled  for site will use this 
analysis center designation. Site poolability will 
also be assessed as described in Sections 10.3.1 and 10.3.2. Change Number Section # / Name [CONTACT_563679] 17 Section 10.3.5, Sensitivity Analyses of the Co-Primary Text was added that specified increments used for the GSP co -primary endpoint for Sensitivity 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 98 of 102 
CONFIDE NTIAL               06 AUG 2020  
Efficacy Endpoints Analysis 4.  Original Text  Missing values will be multiply imputed via this PHWKRGZLWKLQFUHDVLQJ«ªYDOXHV7KH*63FR -
primary efficacy outcome analysis methodology 
will be applied to the imputed datasets and repeated 
until statistical significance no longer holds. The 
tippi[INVESTIGATOR_563633].  
For the HDSM -Ax-7 co-primary endpoint, identical 
imputation methodology to that described above for 
the GSP will be applied to the HDSM -Ax-7 total 
scores, and the resulting values will be 
dichotomized into responders versus non -responders using the 2-point improvement criterion.    
 Revised Text  Missing values will be multiply imputed via this PHWKRGZLWKLQFUHDVLQJ«ªYDOXHV $«ªLQFUHPHQWRI
5 mg will be used for this study.  The GSP co -
primary efficacy outcome analysis methodology 
will be applied to the imputed datasets and repeated 
until statistical si gnificance no longer holds. The 
tippi[INVESTIGATOR_563633].  
For the HDSM -Ax-7 co-primary endpoint, identical 
imputation methodology to that described above for 
the GSP will be applied to the HDSM -Ax-7 total 
scores, and the resulting values will be 
dichotomized into responders versus non -
responders using the  2-point improvement  criterion. 
$«ªLQFUHPHQWRI on a 0 -4 scale) will be used 
for this study.  
 Change Number Section # / Name [CONTACT_563679] 18 Section 10.3.5, Sensitivity Analyses 
of the Co -Primary Efficacy Endpoints Details were added regarding the sensitivity analysis.  
 Original Text  Sensitivity Analysis 5: A sensitivity analysis will be conducted to investigate whether any of the 
individual items in the HDSM -Ax-7 scale are 
overly influencing changes observed in the total 
score. The primary analysis for HDSM -Ax-7 will be repeated for each of the 7 individual items. 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 99 of 102 
CONFIDE NTIAL               06 AUG 2020  
 Revised Text  Sensitivity Analysis 5: A sensitivity analysis will be conducted to investigate whether any of the 
individual items in the HDSM -Ax-[ADDRESS_740611] a 2 -point 
improvement in the individual question from 
baseline to EOT. The logistic regression model for 
the primary analysis for HDSM -Ax-7 will be 
repeated for each of the 7 individual items, and 
each individual ques tion will be analyzed 
separately. Secondly, one of the 7 items will be 
omitted, and the HDSM -Ax-7 total score will be 
calculated as the average of the remaining 6 items. 
The primary logistic regression analysis for 2 -point 
improvement response rate will be  performed on 
this 6 -item scale. This process will be repeated 7 
times, each time with a different item of the 
HDSM -Ax-7 scale removed from calculation of the overall score  Change Number Section # / Name [CONTACT_563679] [ADDRESS_740612]. All other 
exploratory  efficacy endpoints  that involve a 
proportion of responders will be analyzed using 
methods similar to what was described for the HDSM-Ax-7 co-primary endpoint. All other 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 100 of 102 
CONFIDE NTIAL               06 AUG 2020  
exploratory endpoints that involve a change from baseline to a single timepoint will be analyzed 
using methods similar to what is described for the 
GSP co-primary  endpoint.  P-values for exploratory 
efficacy endpoints will be provided for descriptive 
purposes only and no formal hypothesis testing will 
occur. All exploratory efficacy analyses will be 
based on available data and missing GSP and HDSM-Ax EOT data imputed.  Change Number Section # / Name [CONTACT_563679] 20 Section 10.4,  
Safety Analyses  Additional items were included [(e) through (i)], which specify tabulated summaries to be produced 
for TEAEs.  Additional text was added specifying the definition of subject severity.  Revised Text  (e) protocol treatment-related serious TEAEs, (f) severe TEAEs, (g) TEAEs leading to dose 
interruption, (h) TEAEs of special interest, and (i) 
anticholinergic TEAEs ‚Ä¶For any symptoms, 
subject severity is the worst severity of the two 
axillae.  
 Change Number Section # / Name [CONTACT_563679] [ADDRESS_740613] (two -sided p < 0.05) for 
both co-primary efficacy endpoints simultaneously 
is greater than 0.90 (with greater than 0.95 power 
for each of HDSM -Ax-7 and GSP).  
Assuming missing data from approximately 15% of 
subjects, a total of [ADDRESS_740614] (two -sided p < 0.05) for both co-primary efficacy endpoints 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 101 of 102 
CONFIDE NTIAL               06 AUG 2020  
simultaneously is greater than 0.90 (with greater than 0.95 power for each of HDSM -Ax-7 and 
GSP).  
Assuming missing data from approximately 15% of 
subject s, a total of [ADDRESS_740615] deviation of approximately 
170 was used for this purpose. This yielded a 
reduced sample size estimate compared with the 
target of 300 subjects completing the co -primary 
efficacy assessments in order to achieve 0.95 power 
for GSP, further indicating that our sample size 
estimations are con servative.  
 Change Number Section # / Name [CONTACT_563679] 22 Section 12.7, Monitoring by [CONTACT_563674] -19 
conditions.   Original Text A representative of the Sponsor will monitor the study on a periodic basis. The determination of the 
extent and nature of monitoring will be based on 
considerations such as the objective, purpose, 
design, complexity, size, and endpoints of the 
study.  
Authorized representatives of  Brickell Biotech, Inc. 
and/or regulatory authority representatives will 
conduct on site visits to review, audit, and copy 
study -related documents. These representatives will 
meet with the Investigator(s) and appropriate staff 
at mutually convenient times to discuss study -
related data and questions.   Revised Text A representative of the Sponsor will monitor the study on a periodic basis. The determination of the 
extent and nature of monitoring will be based on 
considerations such as the objective, purpose,  
design, complexity, size, and endpoints of the 
study. In the event of interruptions to site accessibility due to COVID-19 or other pandemics 
Sofpi[INVESTIGATOR_563572] -4000 -CL-302/03  Page 102 of 102 
CONFIDE NTIAL               06 AUG 2020  
conditions, alternative means of monitoring the study documents may be implemented, as allowed 
by [CONTACT_563675] l requirements, such as remote 
monitoring and/or data verification.  
Authorized representatives of Brickell Biotech, Inc. 
and/or regulatory authority representatives will 
conduct on site visits to review, audit, and copy 
study -related documents. These repre sentatives will 
meet with the Investigator(s) and appropriate staff 
at mutually convenient times to discuss study -related data and questions.  
 